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Characterizing the critical role of metabolic and redox 
homeostasis in colorectal cancer 
Abstract 
Danielle E. Frodyma, Ph.D. 
University of Nebraska Medical Center, 2020 
Supervisor: Robert E. Lewis, Ph.D. 
Metabolic alterations are a hallmark of cancer and the mechanism by which these 
adaptations sustain cancer cell growth are complex and dependent on tissue type. In colon cancer, 
Peroxisome Proliferator Activated Receptor γ Coactivator 1 β (PGC1𝛽) and Estrogen-Related 
Receptor α (ERR𝛼) are overexpressed and contribute to tumor growth. Previous studies have 
shown that PGC1𝛽 and ERR𝛼 regulate many metabolic processes by controlling vital gene 
expression. Here, we show that PGC1𝛽 and ERR𝛼 drive oxidative phosphorylation and glycolysis 
in colon cancer cell lines and we evaluated downstream effectors and processes.  
A dysfunction in the reductive and oxidative capacity of the cell often aligns with 
dysfunction in metabolism. Data presented here show that Nrf2, a transcription factor that 
activates antioxidant response genes, also regulates PGC1𝛽 and ERR𝛼 protein expression. 
Similarly, we also showed K-Ras, a common oncogenic driver in colon cancer, as a regulator of 
Nrf2 protein expression. However, we determined that the mitochondria following PGC1𝛽 
depletion were at optimal polarity compared to the control cells, but not with Nrf2 knockdown, 
suggesting PGC1𝛽 can function independently of its regulation by Nrf2. These data led to the 
investigation of downstream effectors of PGC1𝛽 and ERR𝛼 to understand the mechanism by 
which the metabolic alterations occur.  
Our data further determined that mitochondrial phosphoenolpyruvate carboxykinase 2 
(PCK2), an essential enzyme at the junction of the TCA cycle and glycolysis, is regulated by both 
PGC1𝛽 and ERR𝛼 expression. While depletion of PCK2 has a minimal effect on the metabolism 
and cell viability of immortalized, non-transformed human colon epithelial cells, PCK2 
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knockdown suppresses oxidative phosphorylation and glycolytic metabolism and decreases cell 
survival in human colon cancer cells. Elevated concentrations of glucose, but not glutamine, 
rescue the metabolic effect of PCK2 depletion. PCK2 depletion also leads to a significant buildup 
in TCA cycle intermediate oxaloacetate, significantly altering flux through malate dehydrogenase 
correlating with diminished glycolytic and oxidative phosphorylation processes. These findings 
suggest that the PGC1𝛽 and ERR𝛼-dependent regulation of PCK2 represents a molecular 
mechanism used by colon cancer cells to maximize metabolic processes and promote cancer 
growth and survival. Overall, the PGC1𝛽 signaling axis is a vital hub of redox and metabolic 
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Cancer is defined as the uncontrollable growth and spread of abnormal cells. Colorectal 
cancer (CRC) is an abnormal growth that occurs in the colon or rectum2. In 2020, it was predicted 
there would be nearly 150,000 new patients diagnosed with CRC. It is the third most common 
cancer diagnosed in women and men3. The population of individuals who suffer from CRC is 
generally over the age of 55, though the incidence has been declining over the last 40 years. 
Surprisingly, the incidence of CRC in younger individuals has increased slightly, which is not 
well understood. However, it is thought to be due to a rising trend in familial cases, screening 
done primarily later in life, and poor diets accompanied by sedentary lifestyles4.  
The estimated number of deaths from CRC was predicted to be 53,200 in 2020. This 
statistic is half of what it was in 1970. This significant decrease in death rate can be attributed to 
an increase in screening and a reduction of modifiable risk factors. New guidelines recommend 
that average-risk individuals over the age of 45 get screened for CRC through a colonoscopy 
procedure every ten years were instrumental in decreasing the mortality rate of CRC. Similarly, 
an increase in physical activity, a decrease in smoking, and healthier diets have assisted in 
reducing the number of deaths caused by CRC2. 
 
CRC Development 
CRC ultimately develops through a series of mutations. First, APC mutations are present. 
APC is a tumor suppressive gene that regulates the frequency of cell division5. Following this 
mutation, it can take many decades for cancer to progress to an early adenoma6. Then, K-Ras and 
BRAF mutations occur. After 2-5 years intermediate adenoma forms, leading eventually to a 
precancerous lesion7. Next, a mutation in SMAD4 is observed and the precancerous lesion 
progresses to a late adenoma. Lastly, TP53 mutations lead to microsatellite stable colorectal 
cancer8,9. Although not all CRC tumors have this detailed mutational profile, given this general 




K-Ras mutations are used to stage and treat CRC in affected patients10,11.    
 
Treatment 
Following CRC diagnosis, a patient will likely undergo surgical treatment to remove the 
precancerous or cancerous lesions. Depending on the stage of the disease and personal health 
factors, preoperative radiotherapy may be performed instead of postoperative radiotherapy12. 
Chemotherapies, such as fluorouracil and oxaliplatin, are considered standard-of-care in the 
treatment of CRC13-16, while irinotecan is best used for metastatic disease17-19. Oxaliplatin fights 
CRC by inhibiting DNA synthesis through inter- and intra-strand DNA crosslinks leading to an 
untargeted cytotoxic effect20. Fluorouracil acts as a pyrimidine synthesis inhibitor resulting in 
untargeted death of rapidly dividing cells21. Irinotecan acts through topoisomerase-1 inhibition 
and ultimately leads to inhibition of DNA replication and transcription22.  
 Stage IV CRC is the most aggressive stage and patients diagnosed at this stage have 
metastatic disease. The most common site of CRC metastases is the liver or lung, for which only 
a small portion of patients receive a surgical reduction. K-Ras mutation status is often correlated 
with tumor aggressiveness and can predict metastatic CRC responsiveness to therapeutics 
targeting EGFR23. However, other mutated genes such as BRAF and PTEN may also play a role 
in therapeutic effectiveness on metastatic disease24,25. Patients presenting with BRAF mutations 
but wild type K-Ras have a poorer prognosis with an increase in metastatic disease. There is 
controversy in the field on how accurate PTEN status is for predicting the treatment of patients 
with metastatic CRC26. It is clear that advanced therapeutic options and better predictive models 
are necessary for the treatment of primary and metastatic CRC.  
 
Ras-mutated cancers 




through multiple pathways and are commonly mutated in human cancers to yield constitutively 
active small GTPases. Activating Ras mutations are found in approximately 25% of human 
tumors, though these three small GTPases are not mutated at equivalent frequencies in cancer. A 
total of 85% of Ras-driven cancers have activating mutations in K-Ras, while N-Ras and H-Ras 
are mutated in 12% and 3%, respectively, of these cancers (http://cancer.sanger.ac.uk/cosmic).  
Ras mutations are most common in pancreatic ductal adenocarcinomas (95%), colorectal 
adenocarcinomas (52%), and lung adenocarcinomas (31%). Intensive analysis revealed that 
multiple effectors with Ras-binding domains (or Ras association domains) could interact with the 
Ras effector loop and mediate its biological effects27. Observations that activating K-Ras and 
RAF mutations are typically mutually exclusive28-30, and that only components of the 
RAF/MEK/ERK pathway rescue growth in Ras-less mouse embryo fibroblasts (MEFs)31, suggest 
that the interaction of Ras with RAF, and the activation of MEK1/2 and ERK1/2, may be the 
most critical to Ras-driven cancers.  
In normal cells, K-Ras is allosterically activated in response to upstream signaling 
generally acts as a molecular on/off switch. One result of activation is initiating a kinase cascade 
including RAF, MEK, and ERK to enhance downstream proliferation, cell survival, and DNA 
repair pathways. Once the intrinsic enzymatic activity of K-Ras cleaves the terminal phosphate of 
GTP to form GDP, K-Ras is no longer active. Proteins such as GTPase-Activating Protein (GAP) 
and Guanine Nucleotide Exchange Factor (GEF) help amplify the activation or deactivation of K-
Ras32. These proteins decrease proliferation and growth signals. Other pathways activated 
downstream of mutant KRAS include PI3K/AKT and NF-κB33. When mutated, such as the 
common K-RasG12C mutation, there is interference with GAP binding, leaving K-Ras 
constitutively active34. Other mutant K-Ras mechanisms include diminished GTPase activity and 






In CRC, mutational activation of Ras is a critical genetic driver in 52% of tumors leading 
to initiation and progression35-37. Ras mutations in CRC account for driving tumorigenesis, 
metastases and determinants of therapeutic regimens38. Although there are therapeutic 
interventions targeting the mutant G12C variant of K-Ras, direct inhibition of mutant Ras 
isoforms remains therapeutically challenging39. There have been several strategies to target K-Ras 
directly. One of these is targeting different sites of K-Ras. This involves a small molecule binding 
to K-Ras to compete with the K-Ras-SOS interaction and prevent GTP activation40,41. Another 
group sought to inhibit the interaction between GTP-bound Ras and RAF, which showed mildly 
promising results in CRC xenograft42. These inhibitors have the possibility to target wildtype K-
Ras as well, making them potentially toxic to patients. Therefore, one group identified a small 
molecule that targets the cysteine on K-RasG12C, making it mutant-specific43. However, the mutant 
K-Ras isoform is so potent it often impairs wild type K-Ras when dimerized together44. Similarly, 
these inhibitors do not interfere with constitutive membrane association, which can lead to 
aberrant growth signaling  through activation of downstream kinases in the RAF/MEK/ERK 
cascade45. 
Beyond these approaches, groups have looked into targeting the G4 structures of the K-
Ras protein to induce transcriptional silencing46-48. Another promising strategy was targeting K-
Ras using microRNAs to silence gene expression at the post-transcriptional level by binding to 
specific regions in the 3’UTR of K-Ras mRNA49-51. However, the genetic heterogeneity of K-
Ras-mutant cancers enhances the challenge of finding an appropriate therapeutic for this 
commonly mutated protein52. Despite decades of research that have been dedicated to K-Ras 
inhibition, there are currently no drugs that either target K-Ras activating mutations or inhibiting 
K-Ras mRNA or protein that are available in clinical trials.  
Although it is discouraging that K-Ras itself has not been successfully targeted, 




available in the clinic. BRAF mutations are present in many other cancers, making BRAF 
inhibitors highly effective for a wide range of patients. ERK inhibitors are the choice of targeted 
therapy for tumors resistant to BRAF/MEK inhibitors53. The effectiveness of therapies in the 
clinic, especially those targeting the RAF/MEK/ERK pathway, is often limited by acquired 
resistance52.  However, patients treated with ERK inhibitors ultimately suffer from resistance as 
well54,55. BRAF inhibitors have been successful for melanoma cancers. Though resistance can 
occur, combination therapy with MEK or ERK inhibitors can alleviate negative outcomes. MEK 
and ERK inhibitors have been used in combination in RAS mutant melanoma models56. 
 
Kinase Suppressor of Ras 1 
Kinase Suppressor of Ras 1 (KSR1) interacts with RAF, MEK, and ERK 57-63, mediates 
ERK activation and signaling in a dose-dependent fashion (discussed in greater detail below), and 
is essential for the transformation of MEFs by oncogenic Ras 59,64. These discoveries revealed a 
critical role played by this molecular scaffold in transformation and tumorigenesis. However, 
KSR1-/- mice are fertile and show inconsequential developmental alterations 63,65. These 
observations suggest that KSR1 may play a prominent role in cancers that are dependent upon 
Ras and ERK signaling, and that it might be exploited therapeutically with minimal toxicity to the 
patient.  
As expected of true scaffolds, increasing KSR1 allows for increased ERK activation until 
KSR1 reaches an optimal level. Surprisingly, in mouse embryo fibroblasts the level of KSR1 that 
maximizes ERK activation and signaling is approximately 12 times the endogenous level of 
expression. Further increasing KSR1 causes a decrease in ERK activation because the cellular 
concentration of KSR1 exceeds the amount of scaffold that can coordinate signaling with Raf, 
MEK and ERK59,66. This suggests that overexpression of KSR1 sequesters the individual 
components of the MAPK cascade such that they are unable to interact, which reduces MAPK 




suppress the inhibitory effects of scaffold excess 60. This observation likely explains why early 
studies in which ectopic KSR1 was overexpressed suggested that KSR1 inhibited Ras-driven 
transformation 67-70. Notably, the level of KSR1 expression that optimizes ERK activation is the 
same level that maximizes the transforming activity of oncogenic Ras and the proliferative effects 
of growth factors 59.   
Phosphorylation sites and determinants of protein-protein interaction have been mapped 
extensively on KSR1 and KSR2 and have been shown to regulate KSR1 in part through 
subcellular localization 71-77. Analysis of these phosphorylation sites and interactions with 
effectors and modifiers suggest dynamic regulation of KSR1 and its scaffold function. Interaction 
with the E3 ligase IMP promotes the redistribution of KSR1 to Triton-resistant punctate 
structures that sequester KSR1 and impair ERK activation 78,79. Phosphorylation of KSR1 on 
Ser297 and Ser392 (Ser310 and Ser469 in KSR2) by the kinase MARK3 (also known as 
CTAK1), creates a 14-3-3 binding site that anchors KSR1 within the cytoplasm (Figure 1.1A) 
64,68,78,80-84. Ras activation catalyzes IMP autopolyubiquitylation, and proteasomal destruction 
(Figure 1.1B) 79. Stimuli that promote IMP degradation also promote dephosphorylation of KSR1 
at Ser392 by PP2A, which eliminates 14-3-3 binding (Figure 1.1B) 75,82,85. Calcineurin 
dephosphorylates 14-3-3 binding sites on KSR2 80. Following the dephosphorylation by PP2A, 
KSR1 is redistributed to the plasma membrane, facilitating the activation of MEK by Raf (Figure 
1.1C). MEK is bound to KSR1 in the absence of Ras activation 86. Though identified as a loss-of-
function mutation on KSR1 in C. elegans 84,87,88, mutation of KSR1 at Cys809 to tyrosine 
(C809Y) enhances the activation of ERK in mammalian cells 64. These observations suggest that 
KSR proteins may sequester MEK in an inactivated state and present MEK for phosphorylation 
by Raf 89,90. In this model, MEK does not need to be in complex with KSR1 to phosphorylate and 
activate ERK. However, KSR1 contains a DEF domain 91, which is essential to KSR1-mediated 
ERK interaction and critical for competent signal transduction 64,74. KSR1 (but not KSR2) also 





Figure. 1.1: KSR1 dynamically regulates the Raf/MEK/ERK kinase cascade. (A) KSR1 is 
constitutively bound to MEK1/2 and IMP. CTAK1 phosphorylates (yellow circle) KSR1 at 
Ser392 allowing for 14-3-3 binding and cytoplasmic localization of KSR1. (B) Upon Ras 
activation and GTP binding, IMP dissociates from KSR1, binds Ras, autoubiquitylates, and is 
degraded. PP2A dephosphorylates KSR1 at Ser392 inhibiting the 14-3-3 binding site anchoring 
KSR1. (C) KSR1 and MEK1/2 translocate to the plasma membrane where KSR1 interacts with 
Raf and MEK1/2 is phosphorylated and activated. (D) MEK1/2 dissociates from KSR1, ERK1/2 





the plasma membrane, and ERK activation (Figure 1.1C-D) 92,93. Another level of KSR1 
regulation exists in its degradation.  Recently, it has been shown that KSR1 is polyubiquitinated 
by praja2, which promotes KSR1 degradation causing a decrease in ERK signaling 94. 
Reconciling these observations implies that KSR1 coordinates a dynamic mechanism that 
provides spatial and temporal control of signaling through the Raf/MEK/ERK kinase cascade. 
 
Phenotypic effects of KSR1/2 genetic inactivation 
Genetic studies in model organisms demonstrate that KSR proteins promote Ras 
signaling 87,88,95. Heterozygous loss of Ksr in Drosophila suppresses RasG12V signaling and 
prevents the rough eye phenotype caused by constitutive Ras signaling 68,87. Similarly, loss-of-
function mutations in ksr1 suppressed the multiple vulva phenotype of activated Ras in C. 
elegans 85. KSR1 plays a similar role in mammals. Apart from minor deficits, ksr1-/- knockout 
mice are fertile and developmentally normal. Ksr1-/- mice have hair follicle defects similar to the 
phenotype of Egfr-/- mice supporting the suggestion that these proteins function within the same 
pathway 63,65,96. As a result of reduced ERK signaling, Ksr1-/- mice have a marginally impaired 
immunological response 57,63,97,98. The most profound and translationally significant phenotype of 
Ksr1-/- mice is resistance to Ras-dependent tumor formation. Skin tumor induction by v-Ha-Ras is 
lost in Ksr1-/- mice 65, and mammary tumor burden is markedly reduced by KSR1 disruption in 
mice expressing transgenic polyomavirus Middle T-Antigen 63. These observations demonstrate 
that KSR modulates Ras signaling in vivo, but it is largely dispensable for normal cell survival. 
The requirement for KSR1 in Ras-driven tumor formation but not normal development reveals 
KSR1 as a potential target for therapeutic intervention. 
 
Structural properties of KSR proteins 




CA5 87. CA1 is located on the N-terminal end and the 40 amino acids in CA1 contribute to B-Raf 
binding by KSR1 and encode coiled-coil and sterile-α-motif (SAM) structures that promote 
KSR1 membrane association 64,74,86,99. CA2 is a proline-rich region without known function. A 
region in KSR2 between CA2 and CA3 is required for KSR interaction with AMPK, and 
mutations in this region inhibit this interaction 71,100,101. CA3 is a cysteine-rich region containing 
an atypical C1 motif homologous to the cysteine-rich CR1 region in Raf that also contributes to 
KSR1 membrane localization 90,102. CA3 mediates the membrane localization of KSR by 
recruiting phospholipids, but does not react to phorbol esters, ceramide, or interact directly with 
Ras 103. CA4 is a serine/threonine-rich region that mediates interactions with ERK through an 
FXFP motif 72. This interaction is not constitutive but requires Ras activation 73,84,90,99,103. The 
CA5 domain in KSR proteins encodes a kinase (or pseudokinase) domain highly homologous to 
Raf family CR3 kinase domains 87,95. Mammalian KSR proteins contain multiple alterations in 
amino acids typically required for catalytic activity including an arginine in place of the lysine 
that coordinates the gamma phosphate of ATP 87,99. Substantial effort has been exerted to clarify 
if KSR can or does phosphorylate cellular substrates, and if so whether or not this activity 
contributes to the downstream effects of KSR 77,90,104,105. KSR1 substrates and the biological 
relevance of any residual phosphotransferase activity have yet to be validated. 
The CA5 region contributes to KSR interaction with MEK in both quiescent and growth 
factor activated cells 71,86,106. Amino acid substitutions within the CA5 region that diminish 
interaction with MEK also reduce ERK signaling 86-88,95,106. However, these alterations are within 
or near the ATP binding domain and may disrupt ATP binding, potentially affecting interaction 
with MEK secondarily. The CA5 domain also interacts with Raf, but the mechanism is 
incompletely understood 74. Thus, there may be unidentified dynamic interactions between the 
CA1 and CA5 domains of KSR proteins and B-Raf that regulate Raf kinase activation, MEK 





KSR proteins as targets for therapy 
Given the importance of KSR1 in modulating signaling through the Raf/MEK/ERK 
kinase cascade in tumor cells and observations that Ksr1-/- mice develop with only 
inconsequential phenotypic differences, targeting KSR1 or KSR1-dependent signaling pathways 
in Ras-driven cancers may selectively affect cancer cells with reduced toxicity to patients. 
Supporting this strategy, RNAi approaches depleting cancer cells of KSR1 in vitro and in vivo 
caused a decrease in tumor growth. Continuous infusion of phosphorothioate antisense 
oligonucleotides targeting KSR1 mRNA also caused regression of established tumors and 
inhibited metastases without overt toxicity in Ras-driven PANC-1 pancreatic and A549 non-small 
cell lung cancer xenografts 107. 
Mutations in KSR that suppress signaling by activated Ras are often adjacent to the ATP-
binding pocket 87,88,95. Furthermore, KSR1 binds ATP 106 and mutations that prevent that binding 
impair ERK activation 108. These observations suggest that manipulation of the ATP binding cleft 
in KSR1 may be therapeutically effective. The recently discovered small molecule APS-2-79 
binds and stabilizes KSR kinase domains in an inactive conformation observed when the KSR2 
kinase domain is bound to MEK1 and ATP 105, interferes with KSR:Raf heterodimerization, and 
inhibits oncogenic Ras signaling 109. The effect of APS-2-79 was also lost when KSR was 
mutated within the active site (A690F) such that KSR can promote MEK phosphorylation even in 
the absence of ATP binding. APS-2-79 modestly decreased cell viability in two Ras-mutated 
cancer cell lines (HCT116 and A549) and did not affect Raf-mutated cancer cells (A375 and SK-
MEL-293), but did demonstrate substantial synergy in Ras-mutated cancer cells with MEK 
inhibitors, suggesting the potential to target both kinase and scaffolding components of the Ras 
signaling pathway in Ras-dependent cancers 109. 
The observation that KSR1 expression was required for tumor-dependent ERK signaling, 




pathways in tumor cells might reveal additional putative targets for cancer therapy that 
preferentially support tumor cell growth and viability. A microarray analysis of downstream 
KSR1 genes showed that PGC and ERR proteins can cause the downstream effects seen with 
KSR1 knockdown110. Subsequently, a gene expression high throughput screen termed Functional 
Signature Ontology (FUSION) was developed to detect effectors of KSR1-dependent signaling in 
Ras-driven tumors and identify small molecules that can target those effectors 111. FUSION 
detected hits that mediate KSR1-dependent signals and promote the viability of human colon 
tumor cells but have no similar role in non-transformed human colon epithelial cells 112,113. These 
observations suggest the existence of multiple effectors that may be used to support the survival 
in tumor cells in a manner distinct from their role in normal tissue. While many genes and 
pathways were identified through analysis of the FUSION screen, one main set of genes most 
significantly evaluated were circadian rhythm genes. Specifically, a lesser-known circadian 
rhythm gene called TIMELESS was a product from the analysis. Further analysis was performed 




Cancer cells alter their cellular metabolism by changing metabolite flux, preferentially 
using nutrients, and priming the microenvironment for enhanced growth. Two main carbon 
sources, glucose and glutamine, play integral roles for the reworking of the metabolic system in 
colon cancers114. Cancer cells increase the consumption of glucose molecules compared to 
nonproliferating cells, which has been used as a diagnostic tool and a cancer specific vulnerability 
termed “The Warburg Effect”115. On the other hand, glutamine contributes to the nitrogen 
requirement of cancer cells. This includes the role that glutamine plays in the synthesis of purine 
and pyrimidines as well as essential and nonessential amino acids116. Tracking the whereabouts of 




possible117,118. Growth factor signaling is oftentimes related to the increase in nutrient uptake that 
cancer cells exhibit119. Paradoxically, the influx of nutrients into the cell is not linked to the 
maintenance of cellular bioenergetics. The pathways in which these carbon sources are utilized to 
increase the concentration of biosynthetic intermediates and ultimately enhance cellular 
metabolism are vast, but vitally important to understand basic cancer biology.  
 
Glycolysis 
The process of glycolysis, the pathway of converting glucose into usable energy, is 
typically performed in the absence of oxygen120. However, cancer cells adapt to low oxygen 
conditions and therefore adjust to undergoing glycolysis as a form of energy generation115,121. In 
CRC, glycolysis can even occur in the presence of oxygen, through induction of Caveolin-1 
signaling122. Cancer cells rely on glycolysis as a form of energy, despite the inefficiency of 
glycolysis compared to other energy-generating pathways, such as oxidative phosphorylation. 
Mitochondrial respiratory defects and hypoxia are thought to contribute to this paradox. 
A byproduct of glycolysis, lactate, can be used as a fuel source in cancer, expanding the 
metabolic function of the cell123. In fact, it was shown in non-small cell lung cancer that lactate 
contributes as a respiratory fuel and its utilization exceeds that of glucose124. Given the important 
implications of glycolysis, its inhibition has been proven to be a useful cancer therapy125,126. 
These therapies include 2-deoxy-glucose, which inhibits the first step of glycolysis and prevents 
ATP formation127,128 and fasentin, which inhibits glucose transportation129. Similarly, inhibition of 





Pentose Phosphate Pathway 
The pentose phosphate pathway (PPP) is a pathway that branches off from glycolysis and 
is a major source of NADPH, a robust reduction agent132-134. The oxidative phase of PPP includes 
the reduction of NADP to generate NADPH and the non-oxidative phase synthesizes sugars. 
These two phases are critical for fatty acid synthesis, pyruvate oxidation and other metabolic 
functions. Cancer cells rely on the PPP specifically because of the cell survival benefits it 
provides under stressful conditions. Described as a vital tumor suppressor, TP53 has been thought 
to inhibit PPP by hindering the activity of glucose transporter genes135. TP53 has also been shown 
to inhibit the expression of PGAM1, which decreases levels of 3-Phosphoglycerate, effectively 
diminishing the PPP136,137. Oncogenic K-Ras has been shown to upregulate the nonoxidative PPP, 
leaving the oxidative PPP branch unaffected138. The mechanism by which this occurs is through 
the induction of HK2 by activated K-Ras. Upon HK2 induction, there is an increase in glucose 
flux to generate Glucose-6-Phosphate, a key PPP intermediate that can also play a role in other 
metabolic pathways139. Similarly, mTORC1, which is frequently activated in cancer, significantly 
upregulates the oxidative PPP by increasing the activity of SREBP, causing an indirect increase 
of Glucose-6-Phosphate. This increase in oxidative PPP results in more NADPH for fatty acid 
synthesis140 and subsequent cancer progression. Lastly, Nrf2 can also increase PPP through 
transcription of multiple key enzymes141. Overall, increased PPP can lead to enhanced oxidative 
stress response, increased cellular maintenance following ionizing radiation, and damage repair 
after chemotherapy regimens142-144. Taken together, the PPP increases cancer cell viability and 
decreases apoptosis making it a vital pathway in metabolic reprogramming.  
 
Gluconeogenesis 
Compared to normal cells, cancer cells divide and grow at increasing rates resulting in 




the ways that cancer cells overcome this problem is by increasing glucose concentrations through 
the process of gluconeogenesis. Many of the reactions that occur in gluconeogenesis are simply 
glycolytic reactions in reverse. However, there are three reactions distinct to gluconeogenesis that 
cannot be performed in reverse. These include the conversion of oxaloacetate and GTP to 
phosphoenolpyruvate, the conversion of fructose-1,6-bisphosphate to fructose-6-phosphate, and 
the conversion of glucose-6-phosphate to glucose. Inhibitors of these reactions have been thought 
to selectively hinder cancer cell growth while normal cells remain less affected147. Therefore, 
under glucose deprivation, gluconeogenesis might potentially serve as an alternative source of 
biosynthetic precursors.  
Some cancer cells exhibit an increase in gluconeogenic enzymes which may not directly 
correlate to the level of gluconeogenesis. The reason for this is some cancers engage in a 
truncated form of gluconeogenesis to support their specific biosynthetic needs, so the function of 
key enzymes is likely not related to glucose production148. The potential other requirements for 
gluconeogenesis are context-dependent and include biomass precursors, ROS balance, cell 
survival, proliferation, epithelial mesenchymal transition, and cancer stem cell regeneration149. 
Although gluconeogenesis is thought to mainly occur in highly metabolic tissues such as the liver 
and the enzymes necessary were thought to be absent from cancers, gluconeogenesis of some 
form exists in many cancer tissues150. 
 
Oxidative phosphorylation 
Although some evidence has shown that glycolysis is upregulated in certain cancers, 
there is still a need to enhance oxidative phosphorylation (OXPHOS) to produce energy. 
OXPHOS generates ATP by the transport of electrons through a series of transmembrane 




transport chain and utilize NADH, FADH2, and succinate as electron donors. When the electrons 
pass through the different complexes, hydrogen ions are in flux until the final complex, ATP 
synthase, uses the hydrogen ions to drive synthesis of ATP. In cancer, mutations in mitochondrial 
DNA or simply a decreased amount of mitochondrial DNA can decrease the efficacy or 
expression of the complexes in the electron transport chain, causing a malfunction in 
OXPHOS151. Metabolic heterogeneity complicates the role of OXPHOS in some cancers. 
However, it appears that transcriptional upregulation of OXPHOS is possible in some cancers 
such as breast cancer, NSCLC, or lymphomas152-154. Similarly, studies in pancreatic cancer have 
revealed that transcriptional upregulation and reliance on OXPHOS is seen in a Ras-driven 
manner155. Because of this strong reliance, inhibitors of OXPHOS such as metformin, a complex 
V inhibitor, can significantly stall proliferation and growth156. In lung cancer, mutant Ras is 
correlated with an increase in oxygen consumption rate and mutant Ras cells are more sensitive to 
rotenone157.  
 From decades of research, it is clear that metabolic alterations in cancer play a significant 
role in enhancing growth and survival. Metabolic pathways are often upregulated to ensure there 
is sufficient energy and biomass available for the cancer cell to grow uncontrollably. Therefore, 
targeting these pathways and understanding the mechanisms by which they function is of the 
highest importance.  
 
TCA Cycle 
The TCA cycle is a series of reactions that provide precursors for amino acids and 
NADH to be used in other pathways. The process takes place in the mitochondria matrix and 
yields three NADH, one FADH2, and one GTP. The NADH feeds into oxidative phosphorylation 




from the TCA cycle and allow fuel sources, such as glutamine, to enhance their metabolic 
needs114,158. In complex I of the electron transport chain, ROS oxidizes TCA cycle 
intermediates159 thus, the TCA cycle can be a potential site of electron leakage and ROS 
formation160. Therapies targeting glutaminolysis is one of the main strategies currently being 
explored in the clinic to inhibit the TCA cycle due to the increased incidence and dependence on 
glutamine metabolism in cancer cells. Similarly, mutations in isocitrate dehydrogenase 2 (IDH2) 
are increased in cancer causing the conversion of α-ketoglutarate into the oncogenic metabolite, 
2-hydroxyglutarate, making mutant IDH2 another prevalent target for cancer therapy161,162. 
 
Cancer Redox 
Oxygen and nitrogen centered oxidants, also known as a reactive oxygen species (ROS) 
or reactive nitrogen species (RNS) are formed by many cell types in tumors. Oxidative stress in 
the form of ROS or RNS can cause damage to the cells and plays a key role in tumorigenesis163-
165. Usually, oxidative stress manifests in the form of superoxides or hydrogen peroxides as a by-
product of generating ATP within the electron transport chain of the mitochondria166. As 
increased metabolism occurs in cancer cells, there is the byproduct of enhanced ROS 
production167. ROS can be especially harmful to the cell, so NADPH is typically employed to 
reduce the ROS into a usable, less toxic, form168,169. Another way to neutralize the harmful ROS 
production is by employing the antioxidant response system. Genes transcribed with an 
antioxidant response element (ARE) motif include NQO1, HO-1, TRX, and GCLC. Although 
high levels of ROS can be dangerous to the health of normal and tumor cells, moderate levels of 
ROS can act as a promoter of cancer cell growth and proliferation170. Paradoxically, low levels of 
ROS can be cancer growth inhibitory, making the balance of ROS in cancer tightly regulated. It is 
known that tumor cells produce elevated levels of ROS compared to normal cells171. However, it 




vice versa, an increase in ROS causes activation of oncogenes.   
 Regulation of ROS production has been studied in order to find vulnerabilities in cancer 
cells to use as potential therapeutic targets. Growth factors have been shown to stimulate the 
production of superoxides. These include the RAS-RAF-MEK-ERK kinase cascade and AKT 
signaling172,173. It has also been proposed that the use of glycolysis in the presence of oxygen has 
been strategically done by the cancer cell in order to spare oxygen for the production of hydrogen 
peroxide to be used in redox signaling174. Lastly, some cancer cells use apoptotic or necrotic cells 
to gain more ROS to fulfil their metabolic and proliferative needs175. 
 Since antioxidants have been thought to negate the harmful effects of ROS, antioxidants 
were employed as treatment for cancer. Surprisingly, antioxidants did not improve, and in some 
cases even impaired patient outcomes176. This led to the idea that antioxidants in normal cells are 
beneficial to help prevent cancer, but antioxidants in cancer cells can lower ROS to an optimal 
level, allowing the cancer cells to proliferate and signal even more. The finding that increasing 
ROS can lead to a cytotoxic effect is one reason why ionizing radiation has been so effective177. 
Ionizing radiation also leads to activation of p53 and subsequent induction of p21, ultimately 
promoting senescence in cancer cells178. Similarly, chemotherapies have also been used to 
increase ROS to a level that is toxic to cancer cells. Chemotherapeutics such as cisplatin, 
doxorubicin, or 2-deoxy-glucose have been shown to increase ROS levels leading to programmed 
cell death of cancer cells179-184. Although there are different sides to ROS in cancer, it is clear that 
it represents a vulnerability necessary for cancer cells to thrive.  
 
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 𝛽 (PGC1𝛽) 
In order to sustain the increased metabolism in cancer, it is essential to over-express or 




Proliferator-Activated Receptors (PPARs) are a family of nuclear receptors that bind to PPAR 
responsive regulatory elements and control the expression of vital components of metabolic 
networks involved185,186. The coactivators of PPARγ, one of the main isoforms responsible for 
whole-body metabolism187,188, are in the PGC1 family. The three isoforms of PGC1 genes are 
PGC1α, PGC1𝛽, and PRC. PGC1α is extensively studied and shown to be a master regulator of 
mitochondrial biogenesis189. PGC1α regulates genes involved in mitochondria biogenesis, though 
it is primarily located in the nucleus, and is overexpressed in tissues that have a high demand for 
energy190. PGC1α induces the bioenergetic potential and promotes metabolic adaptation to confer 
drug resistance191, being beneficial for cancer cells. Another way PGC1α promotes tumor survival 
and growth is through the use of lactate as an energy source, making its metabolism more 
efficient192. There is some evidence that mTORC, a complex that controls protein synthesis and 
acts a sensor of nutrients, energy, and redox, coordinates with PGC1 family members to enhance 
mitochondrial biogenesis193-196. 
The least studied of the three isoforms is PRC. PRC shares certain characteristics with the 
other PGC1 family members but has its own unique characteristics. PRC is thought to activate 
mitochondrial biogenesis through direct interaction with NRF1 (Nuclear Respiratory Factor 
1)197,198 and indirectly with host cell factor proteins199. Unlike other PGC1 family members, PRC 
mRNA has a relatively short half-life and is upregulated only in proliferating cells197,198. 
Therefore, PRC has been thought to be one of the immediate early genes that are expressed to 
enhance cell growth programs200. 
Lastly, PGC1𝛽 is a nuclear transcriptional co-activator that enhances the activity of 
several transcription factors 201,202. PGC1β binds transcription factors through several LXXLL 
amino acid motifs within the PGC1𝛽 protein6. PGC1𝛽 is critical for mitochondrial biogenesis and 
mitochondrial gene expression203. More recently, a study looked at correlation between PGC1𝛽 




associated with telomere length, making PGC1𝛽 methylation a prime candidate for biomarking 
cancer risk204. In thyroid cancer, BRAF mutations alter PGC1𝛽 signaling, inhibiting 
mitochondrial respiration and enhancing aerobic glycolysis205. BRAF mutations were found to 
correlate with high levels of pERK and to downregulate PGC1𝛽.	This leads to a decrease melanin 
synthesis in melanoma cells, decrease OXPHOS, and increased glycolytic ATP206. PGC1𝛽 
expression is increased in HER2 overexpressing breast tumors. HER2 amplification increased 
PGC1𝛽 mRNA compared to levels in normal breast (MCF10A) cells. Inhibition of PGC1𝛽 
increased citrate synthase activity, caused a decrease in the glycolytic pathway, but led to no 
changes in mitochondrial respiration. PGC1𝛽 knockdown also resulted in an increase in ROS 
without activation of an antioxidant response207. Similarly, PGC1𝛽 has been shown to regulate 
HIF-1α, which inhibits acyl-CoA dehydrogenases, MCAD (medium chain acyl-CoA 
dehydrogenase) and LCAD (long chain acyl-CoA dehydrogenase), which are enzymes that 
catalyze most fatty acid oxidation, resulting in lower ROS levels208. 
 Many colon tumor cell lines with metastatic potential and K-Ras mutations show 
dramatic over-expression of PGC1β protein and mRNA compared to immortalized, but non-
transformed human colon epithelial cells (HCECs)112. PGC1β is also upregulated in human tissue 
from primary colon tumors and liver metastases112. Similarly, PGC1𝛽 is vital for the growth and 
viability of colon cancer cells in vitro and in vivo 112. 5' AMP-activated protein kinase (AMPK), a 
critical regulator of energy homeostasis, is crucial for the expression of PGC1β in CRC cell 
lines112. Our lab has previously published that PGC1β is a critical regulator of tumor survival in 
CRCs with mutant K-Ras112,113. In 2014, Bellafante et al. showed that enterocyte-specific deletion 
of PGC1β protected mice from chemical-induced carcinogenesis, but loss of PGC1β did not have 
any detectable defects in the function of normal colon epithelium209 suggesting that targeting of 





Estrogen Related Receptor 𝛼 (ERR𝛼) 
Estrogen Related Receptor (ERR) proteins are a family of orphan nuclear receptors, 
which means that these receptors’ ligands have not been identified. These proteins serve as 
transcription factors that enhance gene regulation. ERR proteins physically interact with PGC1α 
and PGC1𝛽 at the LXXLL site present on the PGC1 proteins210-213. Similar to the role of PGC1 
proteins, ERR transcription factors have been shown to control energy homeostasis, oxidative 
metabolism, and mitochondrial biogenesis210,213-215. 
 There are three isoforms of human ERR proteins, ERR𝛼, ERRβ, and ERRγ. ERRβ has a 
relatively unknown function. Limited evidence suggests that ERRβ is implicated in embryonic 
stem cell self-renewal since its knockout causes intrauterine lethality216. Similarly, ERRβ has 
been shown to be a prominent early-response gene following MEK inhibition in trophoblast stem 
cells, suggesting that it promotes stem cell-type-specific networks through distinct interaction 
partners that maintain trophoblast stem cell self renewal217. One study has shown that the 
expression of ERRβ is decreased in prostate cancer and activates the p21 promoter inducing 
arrest at S phase, suggesting a tumor suppressive role218,219.  
 An ERRγ agonist, such as Bisphenol A (BPA), may suppress gastric cancer progression. 
ERRγ gene signatures showed improved prognosis due to the suppression of Wnt signaling220. 
ERRγ expression is linked to progression-free survival in both ovarian and breast cancer, while 
expression is downregulated in prostate cancer and medulloblastoma221-224. Although there are no 
known ligands for ERR proteins, 4-hydroxytamoxifen and diethylstilbestrol have been shown to 
act as inverse agonists to deactivate ERRγ225. ERRγ has also been shown to bind strongly to BPA, 
an estrogen-mimicking compound, and its metabolites226-228. Therefore, high BPA accumulation 
correlates with high concentrations of ERRγ, such as in the placenta 229. ERRγ has been shown to 
be necessary to maintain the metabolic switch of energy dependence in the fetal heart and to 




 The last isoform is ERR𝛼. ERR𝛼 was the first discovered ERR protein and was given the 
name because of the structural homology shared with Estrogen Receptor 𝛼. Since inhibition of 
Estrogen Receptors was used as a therapeutic strategy, it was interesting when the discovery was 
made that ERR𝛼 binds a DNA segment with the estrogen-response element232-234. It was later 
confirmed that ERR𝛼 modulated the expression of many estrogen-inducible genes and breast 
cancer prognostic markers233,235,236. Following a genome-wide ChIP analysis, it was shown that 
although there was a small fraction of overlapping genes transcribed by ERR𝛼 compared to ER 
proteins, ERR𝛼 signaling was considered separate from ER signaling237.  
 ERR𝛼 also gave insight into the metabolic function of ERR proteins. In addition to ER 
genes, ERR𝛼 activates the MCAD gene promoter, a vital enzyme that breaks down fatty acids in 
the mitochondria, thereby regulating mitochondrial fatty acid 𝛽-oxidation215,238. In addition, 
ERR𝛼-null mice were  shown to be lean and resistant to diet-induced obesity239. These 
observations led to the identification of ERR proteins as vital players in regulation of energy 
metabolism. In contrast to ERRγ, ERR𝛼 expression is elevated in many tumor samples including 
ovarian, cervical, colorectal, and prostate cancer112,221,240-242. ERR𝛼 proteins have been shown to 
activate glycolytic enzymes in breast cancer and to support the energy demands of increased 
proliferation of cancer cells243. ERR𝛼 binds to the promoter regions of glutamine import genes 
and other genes involved in catabolism, thereby modulating flux through the TCA cycle244. 
 Despite the vital metabolic role of ERR𝛼, whole-body knockout mice were viable with 
little defects245. Therefore, work has been done to develop effective inhibitors. Most of the 
therapeutics developed are designed to block the interaction between ERR𝛼 and PGC1 proteins. 
This includes XCT790, Compound A, and Compound 29246-248. Compound 29 shows significant 
inhibition of breast cancer in combination with PI3K inhibitors248. Similarly, Compound 29 




manner249. XCT790 is a potent inverse agonist ligand of ERR𝛼 while independently uncoupling 
the electron transport chain250. The mechanism of ERR𝛼 inhibition by XCT790 is due to its 
ability to interfere with the ligand-binding domain of ERR𝛼214,250. While the inhibitors of ERR𝛼 
were promising endeavors, they showed significant off-target effects and toxicity in preclinical 
studies and are not approved for clinical use due to these concerns 251,252.  
Objectives and Hypothesis 
Our objectives for this project were to biologically validate the FUSION hit, TIMELESS, 
specifically in regard to it being a vulnerability in cancer similar to KSR1. We sought to 
understand the mechanism in which TIMELESS functioned in order to maintain colon cancer cell 
survival and viability. Since TIMELESS was shown to phenocopy KSR1 functions, we 
hypothesized that it would be necessary for colon cancer cells, yet dispensable for normal cells. 
Similarly, we hypothesized that understanding of the role of TIMELESS in the circadian rhythm 
would further unveil its importance to overall proliferation and survival. Lastly, we hypothesized 
that the literature citing TIMELESS as a component to mitigate DNA damage would hold true in 
colon cancer cells. 
Next, our objectives were to understand the mechanistic role of the PGC1𝛽-ERR𝛼 
signaling axis. Our hypotheses include that the upstream regulators and downstream effectors of 
both PGC1𝛽 and ERR𝛼 in colon cancer would provide a clue as to the underlying mechanisms at 
play. The upstream regulators were hypothesized to mirror PGC1𝛽-dependent phenotypes. 
Similarly, the downstream effectors identified experimentally were hypothesized to play a vital 


















Colorectal cancer cell lines HCT116, T84, SW480, HCT15, SW620, RKO, LoVo, and FET cells 
were purchased from American Type Culture Collection (ATCC) and cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with 10% Fetal Bovine Serum (FBS). All colorectal cancer 
cell lines were grown at 37°C with ambient oxygen (O2) and 5% CO2. Immortalized, non-
transformed human colon epithelial cells (HCEC) were a gift from J. Shay (UT Southwestern). 
HCECs were grown in medium composed of four parts DMEM and one part Medium 199 
(Sigma) with 2% cosmic calf serum (GE Healthcare), 25ng/mL EGF, 1µg/mL hydrocortisone, 
10µg/mL insulin, 2µg/mL transferrin, and 5nM sodium selenite and grown in a hypoxia chamber 
with 2% O2 and 5% CO2 at 37°C.  
 
siRNA Reverse Transfections 
The siRNA oligos (Dharmacon) targeting the protein of interest or non-targeting controls were 
used for targeted depletion of specific proteins from colorectal cancer cells (Appendix C). For 
pooled transfections, two validated, individual ON-TARGET PLUS siRNAs were used at a final 
RNAi concentration of 40nM and added to 5µL of RNAiMAX (ThermoFisher) and 500µL Opti-
MEM. The mixture was added to 300,000 cells in 1.5-2mL of medium in a 6-well plate (BioLite 
Plates, Fisher). HCECs were transfected using the Lipofectamine RNAiMAX reverse transfection 
protocol with 400,000 cells per well and a final concentration of 20nM RNAi. All transfections 
were conducted for 72-hours before analysis.   
 
cDNA Forward Transfection 
Approximately 300,000 cells were plated in a 6-well plate and 24 hours later the forward 
transfection was done. The human NC16 pCDNA3.1 FLAG NRF2 construct (Addgene #36971) 




manufacturers’ protocol. The construct contains a CMV promoter and a FLAG tag on the N-
terminus. The concentration of plasmid DNA was measured using the Nanodrop1000. The 
measurement was converted from ng/μL to μg/μL. 5µg of the DNA was necessary to transfect 
300,000 cells and a 1:1 ratio of DNA to Lipofectamine1000 was used. The DNA was mixed with 
250μL of OptiMEM with the volume of DNA subtracted. The Lipofectamine1000 was mixed 
with OptiMEM in a separate tube. Then, the two tubes were combined and incubated at room 
temperature for 5-15 minutes. Next, the mixture was added dropwise to the cells. Approximately 
48- to 72-hours later the cells were collected.  
 
Cell Count 
Cells were dissociated using trypsin and suspended into an appropriate amount of medium. 10μL 
of the cell mixture was added to a hemocytometer. Each 4x4 square was counted on the 
hemocytometer and averaged. Each count was multiplied by 10,000 to calculate the number of 




The Seahorse XFe96 Metabolic Flux Analyzer (Agilent) was used to measure Oxygen 
Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR). The cells were either 
transfected directly in the Seahorse XF96 Cell Culture Microplate by plating approximately 1x104 
cells per well, or transfected cells were plated into the Microplate 48 hours post-transfection (as 
previously described) at a density of 6x104 cells per well. The day before the experiment, the 
FluxPak plate was hydrated in water and incubated at 32°C with ambient CO2. On the day of the 
experiment, the medium was removed from the cells and the cells were washed with PBS. Then, 




contained 2µM glutamine, 25µM glucose, and 2µM sodium pyruvate, unless otherwise specified. 
The cells were incubated in this medium at 32°C with ambient CO2 for 1 hour prior to beginning 
the experiment. Water was removed from the FluxPak and calibrating medium was added and 
incubated at 32°C with ambient CO2 for an hour prior to the experiment. Drugs were added to the 
FluxPak injection ports in the order in which they were to be injected. To measure OCR, 
oligomycin was added so the final concentration was 2µM in the culture medium. FCCP, a 
mitochondrial uncoupler, was added so the final concentration in the culture medium was 
12.5µM, and rotenone was added so the final concentration was 10µM in the culture medium. To 
measure ECAR, glucose was added so the final concentration was 13mM, oligomycin was added 
so the final concentration was 2µM, and 2-deoxy-glucose (2-DG) was added so the final 
concentration was 120mM. In the event that the cells were transfected in the microplate, the OCR 
and ECAR measurements were normalized to protein levels.   
 
RT-qPCR 
Cells were harvested using 0.5 mL TRIzol (ThermoFisher Scientific) and stored at -80°C until 
RNA extraction was performed. RNA was extracted using RNeasy spin columns (Qiagen) per the 
manufacturer’s protocol. Final RNA was eluted with nuclease-free water and quantified using the 
NanoDrop 2000 (ThermoFisher Scientific). Reverse transcription was performed with 1µg of 
total RNA per 20µL reaction using iScript Reverse Transcription Supermix (Bio-Rad). RT-qPCR 
was performed using primers for proteins of interest or housekeeping gene controls (Appendix 
C). All targets were amplified using SsoAdvanced Universal SYBR Green Supermix (BioRad). 
An R script was generated to implement the qBase analysis as described in the qBase methods 





RNA-Sequencing and analysis 
RNA sequencing (RNA-seq) analysis was conducted by the UNMC DNA Sequencing Core. For 
RNA sequencing, RNA was purified from HCT116 as previously described. Three biological 
replicates of non-targeting control, PGC1𝛽, or ERR𝛼 knockdown were completed using two 
separate oligos for each condition. The transfection and RNA isolation were performed as 
previously described and at least 100µg/µL of RNA was submitted for analysis. Unstranded (poly 
A only) RNA sequencing libraries were prepared per manufactures’ suggested protocol using the 
TrueSeq mRNA Protocol Kit (Illumina) and 500ng of total RNA for each of the samples. Purified 
libraries were pooled at a 0.9pM concentration and sequenced on an Illumina NextSeq550 
instrument and 75 bp paired end sequencing was performed. Libraries were normalized and equal 
volumes were pooled in preparation for sequence analysis. Raw sequence data has been deposited 
as GSE147905.  
 
Sequence reads were preprocessed using XPRESSpipe (v0.4.1) 255. Reads were processed using 
H. sapiens GRCh38.13 Ensembl release 99. Differential expression analysis was performed using 
XPRESSpipe wrapper for DESeq2 (v1.22.1) 256. Differentially expressed genes were further 
visualized using XPRESSplot 255. Isoform abundance analysis was performed using XPRESSpipe 
wrapper for Cufflinks (v2.1.1) 257 and IGV (v2.4.19) 258. Scripts used to perform these analyses 
can be found at https://github.com/j-berg/froydma_2020 
 
Protein Quantification 
Protein quantification in cell lysates was performed to determine the volume needed to load into 
the gel. Tubes or a 96-well plate were used to perform a BCA quantification. 2μL of each BSA 
standard in the concentration of 0mg/mL, 2.5mg/mL, 5mg/mL, 7.5mg/mL, 10mg/mL, and 




number of samples and BSA standards were added and multiplied by 100 to determine the 
volume in μL of Reagent A needed. Then, the number of samples and BSA standards were added 
together and multiplied by two to determine the amount in μL of Reagent B needed. The volume 
of Reagent A is first added to a tube, then Reagent B was added. Immediately, 100μL of the 
mixture was added to the BSA standards and the samples. Incubation for 10 minutes was done in 
a 37ºC incubator. The standards were entered into the Nanodrop1000 software. Once the 10-
minute incubation was complete, a blank was measured and then each standard was measured. 
After an appropriate standard curve was observed, each sample was measured. Approximately 
3μg per 1μL of protein was used for each Western blot sample. The remaining volume contained 
1M DTT, 5X Sample Buffer, and RIPA buffer to dilute. For each experiment, approximately 45-
60μg of protein, or 15-20μL, of sample was added,   
 
Western blot analyses 
Whole cell lysates were prepared in radioimmunoprecipitation assay (RIPA) buffer that was 
comprised of 50mM Tris-HCl, 1% NP-40, 0.5% Na deoxycholate, 0.1% Na dodecyl sulfate, 
150mM NaCl, 2mM EDTA, 2mM EGTA, and addition of a protease and phosphatase inhibitor 
cocktail (Halt, ThermoFisher Scientific). A BCA protein assay (Promega) was used to determine 
protein concentration. An 8% Acrylamide - SDS-PAGE was used to separate the proteins and 
nitrocellulose membranes were blocked in Odyssey TBS blocking buffer (LI-COR Biosciences) 
for at least 30 minutes at room temperature. The primary antibody was allowed to hybridize at 
least overnight at 4°C. The PCK2 (6924), PARP (9542), P-CDK1 (9111), T-CDK1 (77055 and 
9112), P-CHK1S345 (2348), pERK (9106), ERK (9102), H2A.X (2595) and Phospho-Histone 
H2A.XSer139 (2577) antibodies were obtained from Cell Signaling Technologies and used at a 
dilution of 1:1000. The PGC1𝛽 (NBP1-28722) antibody was purchased from NovusBio and used 




used at a dilution of 1:2500. The ERR𝛼 (ab76228), Nrf2 (ab137550), NQO1 (ab34173), KSR1 
(ab68483) and HDAC2 (ab32117) antibodies were purchased from Abcam and used at a dilution 
of 1:1000. The 𝛽-actin (sc-47778), Keap1 (sc-365626), 𝛼-tubulin (B-5-1-2) and pan-Ras (sc-
166691) antibodies were purchased from Santa Cruz Biotechnology and used at a dilution of 
1:1000. IRDye 800CW and 680RD secondary antibodies (LI-COR Biosciences) were diluted 
1:10,000 in 0.1% TBS-Tween and imaged on the Odyssey Scanner (LI-COR Biosciences). 
 
ROS Measurements 
The MitoSOX Red mitochondrial superoxide indicator (ThermoFisher, M36008) was 
resuspended into 13µL of DMSO to make a 5mM stock. On the day of the experiment, a final 
concentration of 5µM MitoSOX was added to the cells in the medium (1:1000 dilution of the 
stock solution). The stain was incubated on the cells for 30 minutes at 37ºC. Mitotracker green 
was also added to the cells. Mitotracker green stock solutions were made to be approximately 
1mM. The final concentration of the Mitotracker green stain was 100nM. The stain was incubated 
on the cells for 30 minutes at 37 ºC. After incubation, the medium was removed, and the cells 
were washed several times with PBS in preparation for flow cytometry analysis.  
 
Anchorage-independent growth on soft agar 
Stable knockdown of PCK2 in HCT116, SW620, and HT-29 cells was achieved using two 
separate oligos of a pLKO-shPCK2-puro construct in addition to a non-targeting control. 
Following lentiviral infection, pools were generated by puromycin selection at 4 μg/mL for 3 
days and validated for PCK2 knockdown. In order to evaluate anchorage independent growth, 
1mL of 1.6% NuSieve agar in water was added to 1mL of sterile 2X RPMI to generate the bottom 
layer of each well of a 6-well plate for each condition. The plates were left at room temperature to 




of 0.8% NuSieve agar in 1X RPMI. This mixture was added to the top of each solidified well. 
Colonies greater than 100μm in diameter were counted. Represent photomicrographs were taken 
after 14 days in culture. 
 
Cell Growth Assay 
Cells were transfected with siRNA targeting PCK2 or a non-targeting control as previously 
described. The next day, cells were counted and approximately 1x104 cells were plated in all 
wells of a 12-well plate for each condition. The next day, three of the wells from each 12-well 
plate were harvested with approximately 25μL of trypsin and 25μL of medium for each well. 
Cells were then counted and recorded. This procedure was repeated for subsequent days up to six 
days post-transfection. The cells from day six were harvested and a Western blot analysis was 
performed to ensure the knockdown of the target protein was maintained. Cell counts were then 
graphed in GraphPad.  
 
Anchorage-independent growth on poly-2-hydroxyethyl methacrylate (polyHEMA)-coated 
plates 
A stock solution of polyHEMA was made by dissolving polyHEMA solid powder in 95% ethanol 
to make a final concentration of 10 mg/mL. The solution was fully dissolved by shaking at 37°C 
overnight. Black-sided, clear-bottom 96-well plates (Nunc) were coated with polyHEMA by 
evaporating 200µL of the stock polyHEMA solution in each well. 48 hours following the 
transfection, approximately 6x104 cells were plated on the coated plates. Cell viability or 
metabolic capacity was measured in relative luminescence using CellTiter-Glo 2.0 Luminescent 
Cell Viability Assay (Promega). Specifically, this was done by adding equal amounts of 
CellTiter-Glo reagent and medium and shaking for two minutes to lyse the cells. The 





Cell metabolic capacity assay  
After 48-hours of transfection, approximately 10,000 transfected cells were plated in each well of 
a white-sided, white-bottom 96-well plate. 24-hours after plating, alamarBlue reagent 
(ThermoFisher Scientific) was added to each well at a 1:10 dilution. Plates were incubated at 
37°C, 5% CO2, for 1-3 hours. Fluorescence was measured using the POLARstar OPTIMA 
machine. Background wells containing only medium and alamarBlue reagent were subtracted 
from the results.  
 
Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) was performed using v.4.0.3 of the GSEA desktop 
application. A ranked list of genes based on log2 fold change and adjusted p-value was used as 
the input and analyzed for enrichment in Kyoto Encyclopedia of Genes and Genome (KEGG) and 
multiple gene sets were identified whose members were enriched with nominal p-value less than 
5%. Single sample Gene set enrichment analysis (ssGSEA) was performed using R Bioconductor 
package gsva (v.1.30.0), to compute separate enrichment scores for each sample and gene set. A 
heatmap of the top 7 pathways was plotted using the ssGSEA score in control, PGC1β and ERRα 
knockdown samples using R Bioconductor package ComplexHeatmap (v.1.20.0).  
 
Mitochondria Membrane Potential Assay 
HCT116 cells were transfected in biological triplicate with either target or non-targeting siRNA 
as previously described. On the day of the experiment, the positive control samples were treated 
with 1µM FCCP for 10 minutes. After the 10-minute incubation, TMRE was added to the cells at 
a concentration of 50nM for 25 minutes. Then, the cells were washed with PBS and harvested 




measured for each sample.  
 
Metabolite Analysis 
HCT116 cells were transfected in five biological replicates, as described above. 72-hours after 
transfection, the cells were harvested and counted. After washing in saline solution, the cell pellet 
was resuspended into 1mL of ice-cold 2:2:1 MeOH: ACN: H2O (v/v/v) containing 10μM stable 
isotope-labeled canonical amino acid mix (Cambridge Isotope Laboratories, Inc) as internal 
standards. The cells were subsequently lysed in a reciprocal shaker with 0.1mm glass beads and 
the samples were centrifuged for 15 minutes at 13,000 rpm at 4°C. The supernatant was removed 
and evaporated to dryness in the SpeedVac. The samples were reconstituted in 100µL of 
resuspension buffer containing 20% ACN and 10mM ammonium acetate, before LC-MS/MS 
analysis.  
 
Chromatographic separation and mass spectrometry detection were performed using a Shimadzu 
Nexera ultra-high-performance liquid chromatography (UHPLC) and triple-quadrupole-ion trap 
hybrid Mass spectrometer (QTRAP 6500 from Sciex, USA), equipped with an ESI source. The 
chromatographic separation of metabolites was achieved on a XSelect (150 x 2.0 mm id; particle 
size 1.7 µm) analytical column maintained at 40°C. The optimum mobile phase consisted of 
10mM tributylamine with 5mM acetic acid in LC-MS grade water containing 2% isopropanol as 
buffer A and isopropanol as solvent B. The gradient elution performed as: time zero to five min, 
0% solvent B; next 4 min, 2% solvent B; 0.5 min, 6% solvent B; 2 min, 6% solvent B; for next 
0.5 min, solvent B was increased to 11% and maintained for 1.5 min; at 35 min, solvent B was 
increased to 28% for next 2 min and then to 53% in 1 min and maintained for next 6.5 min. 
Solvent B was reduced to 0% and maintained to equilibrate column till the next injection. The 




10°C. The data acquisition was under the control of MultiQuant software (Sciex, USA). The mass 
spectrometer was operated in positive and negative ion mode using polarity switching. Ions were 
acquired in multiple reaction monitoring (MRM) mode. MRM details for the selected metabolites 
were as follows: Oxaloacetate, 131.0/ 87.0; Phosphoenolpyruvate, 167.0/ 79.0; Citrate/Isocitrate 
pool, 191.0/ 111.0; Fumarate, 115.0/ 71.0; Succinate, 117.0/ 99.0. The retention time of each 
metabolite was confirmed by the 13C-labelled yeast metabolite extract, which was used as the 
qualitative standard (Cambridge Isotope Laboratories, Inc). Optimized spray voltage was at 5.5 
kV for positive and 4.2 kV for negative mode, ESI source temperature was at 400°C, nitrogen 
was used as curtain gas, gas 1 and gas 2 at pressure 30, 40 and 40 arbitrary units, respectively. 
Declustering potential in positive and negative mode was optimized at 65 and -65 volts. 
 
Propidium Iodine/Annexin V Stain 
A triplicate siRNA transfection was performed 72-hours before the PI/Annexin V stain was done. 
In addition to the siRNA transfection, three wells were plated to use as dead-cell controls. 48-
hours after plating, the cells-only wells were treated with FCCP to ensure some dead or dying 
cells are present at the time of staining. After 72-hours, the medium was collected. The cells were 
washed with PBS and collecting the PBS. Then, the cells were dissociated using trypsin and 
collected. After spinning down the cells and washing with PBS, the cells were counted to ensure 
approximately 400,000 cells per tube. After spinning down the cells, they were resuspended into 
200μL of 1X Binding Buffer in the Dead Cell Apoptosis with Annexin V and PI Kit 
(ThermoFisher, V13242).  5μL of the Annexin V and 1µL of the PI stain was mixed into the 
cells. Each cell line containing an untreated and single-color control. The stain was allowed to 
incubate at room temperature for 15 minutes. Then, 300μL of 1X Binding Buffer was added to 
the samples. The samples were put on ice and incubated for 15 minutes before being analyzed by 





Cell Circadian Rhythm Synchronization 
In experiments in which circadian rhythm was evaluated, the rhythm of the cells was 
synchronized by treating with medium containing 50% horse serum and 50% DMEM for two 
hours. Following the two hours, cells were washed and DMEM medium with 10% FBS was 
added. Cells were collected beginning at the end of the two hours synchronization period and 
every 4-6 hours for the next 24-48 hours. Cells were pelleted and snap frozen in liquid nitrogen 
and stored at -80ºC until all samples were collected. Western blot analysis was performed as 
described in the Western blot analysis section.  
 
Carboxylfluorescein succinimidyl ester (CFSE) Cell Division Assay 
Approximately 2 million colon cancer cells suspended in 1mL of PBS were stained with 10μM 
CFSE. Once the CFSE was added, the suspended cells were incubated at 37ºC for 15 minutes. 
Following the incubation, cells were pelleted and washed with medium. Approximately 300,000 
cells per sample were added to a 6-well plate containing siRNA transfection reagents. After 96 
hours, cells were harvested from the plate and resuspended in PBS for flow cytometry analysis. 
Remaining cells were used to confirm target gene depletion by Western blot.  
 
TCGA 
mRNA expression was analyzed based on the FPKM-UQ normalized RNASeq values of normal 
solid tissue samples and primary tumors from within The Cancer Genome Atlas (TCGA) for 
Colon Adenocarcinoma (COAD). The number of normal samples evaluated was 41 and the 
number of tumor samples evaluated was 285. Results were analyzed for statistical significance 






BCA Reagent A and Reagent B (23221 and 23224) were purchased from ThermoFisher. Poly-2-
hydroxyethyl methacrylate (polyHEMA, P3932), Oligomycin (75351), FCCP (C2920), and 
Rotenone (R8875) were purchased from Sigma. RT-qPCR oligos were purchased from Integrated 
DNA Technologies (IDT). 2-deoxy-glucose (AC111980010) was purchased from Fisher 
Scientific. Glucose (A2494001) was purchased from ThermoFisher. The ERK inhibitor 
SCH772984 was purchased from SelleckChem (S7101). CFSE reagent was purchased from BD 
Horizon (565082).  
 
Statistical Analysis 
P values were calculated using Prism Software (GraphPad, La Jolla, CA). A p value of less than 
0.05 was considered statistically significant. Baseline OCR and Maximum respiratory capacity 
were calculated as previously described 259. Briefly, baseline OCR was calculated by averaging 
the baseline OCR measurements taken by the Seahorse XFe96 machine. Maximum respiratory 
capacity was calculated by subtracting the OCR measurement taken after the addition of 
Rotenone from the OCR measurement taken after the addition of FCCP. Glycolysis and 
glycolytic capacity were calculated as previously described 260. Briefly, glycolysis calculations 
were achieved by subtracting the ECAR readings following the addition of 2-DG from the ECAR 
readings following the addition of glucose. Glycolytic capacity was calculated by subtracting the 
ECAR reading following 2-DG addition from the ECAR reading following oligomycin addition. 
The statistical significance of these results was evaluated using an unpaired, two-sided Student’s 
t-test comparing control to knockdown in each cell line. The cell metabolic capacity assays were 
statistically evaluated using an unpaired, two-sided t-test to compare the effects of target protein 
depletion to control cells. Data are shown as mean +/- standard deviation (SD) unless otherwise 




of biological replicates is stated in terms of the number of independent experiments performed. 










Chapter 3: FUSION hit, TIMELESS, is selectively required for 










Portions of the content covered in this chapter are the subject of a published 





 The FUSION screen of over 14,000 genes was performed to identify vulnerabilities in 
cancer that are functionally similar to KSR1 in HCT116 cells. The screen was performed 
following a microarray of HCT116 cells with and without KSR1 knockdown which led to six 
KSR1-dependent reporter genes including BNIP3, NDRG1, ACSL5, LOXL2, ALDOC and 
BNIP3. The experiment was also performed with two control genes, PPIB and HPRT and the 
overall signature was compared to the systematic RNAi knockdown of an RNAi library.  
After bioinformatic analysis of FUSION, the protein TIMELESS successfully passed all 
the metrics required to name it as a functional analog of KSR1 based on Pearson correlation and 
Euclidian distance.  This is to suggest that TIMELESS regulates a similar gene signature as 
described above.  TIMELESS was originally identified and characterized in Drosophila as a vital 
circadian gene and shares many regions with the mammalian TIMELESS protein such as the 
nuclear localization signal and DEDD sequence261,262. TIMELESS contains a vital N-terminal 
domain that is required for homodimerization and interactions with TIPIN, CHK1, and CRY1 
proteins, which are necessary for circadian regulation261-264.  Similarly, a highly glutamic acid-
rich region is required for DNA binding.  
TIMELESS has been most notably studied as a negative regulator of the circadian 
rhythm265. The circadian rhythm is driven by CLOCK and BMAL binding to E-boxes that 
transcriptionally regulate circadian genes such as PER and TIMELESS266. In some animal 
models, TIMELESS shows a classic 24-hour oscillation and was shown to interact with and 
stabilize the PER1/2 circadian proteins267-269. PER and TIMELESS then inhibits CLOCK and 
BMAL thus halting the circadian cycle266,270. Another regulatory mechanism of TIMELESS is 
through post-translational modifications. Phosphorylation of TIMELESS can promote aberrant 
translocation to the nucleus causing an enhanced circadian period268,271-279. Following an increase 
in light, TIMELESS is degraded through the proteosome280-284 but can also be shunted towards 




Another role that TIMELESS plays is through the process of DNA replication, which 
may be attributed to its KSR1-like functionality. Studies have shown that TIMELESS depletion 
decreases DNA replication and causes genomic instability286,287. TIMELESS localizes to the 
replication fork and leads to a decrease in ssDNA accumulation and prevents DNA damage 288-291. 
Similarly, TIMELESS stimulates activation of several DNA polymerases and promotes high 
fidelity of DNA synthesis292. In addition to the circadian rhythm, TIMELESS is expressed in 
accordance with the cell cycle S and G2 phases293. Thus, it has been shown that depletion of 
TIMELESS can increase defects in mitotic progression291,294. Cancer cells have been shown to 
have increased DNA damage due to bypassing the checkpoints responsible for mitigating cell 
death295-297. Activation of CHK1 through phosphorylation at serine 345 prevents the activation of 
CDK1298,299. TIMELESS interacts with CHK1 to mediate its phosphorylation287,293,300-306. 
Similarly, TIMELESS physically interacts with PARP, leading to accumulation of TIMELESS at 
sites of DNA damage307,308. Inhibitors of PARP can trap TIMELESS at sites of DNA damage, 
though its role at these sites has not been fully elucidated307. 
Dysfunction in the circadian rhythm is oftentimes exhibited in cancer cells and has even 
been shown to play a pro-tumorigenic role309,310. Aside from colon cancer, other cancers such as 
leukemia, breast, cervical, and lung cancers have shown an overexpression of TIMELESS 
compared to normal cells311-317, which is similar to reports from our lab showing KSR1 
overexpressed in colon cancer cell lines compared to normal cells. However, the mechanism of 
TIMELESS, whether it be functioning exclusively as a circadian protein or through the DNA 
damage pathway, appears to be context dependent. Another example of the diversity of 
TIMELESS mechanism is in breast cancer where TIMELESS enhances MYC activity while 
inhibition of MYC downregulates TIMELESS activity314. In the clinic, enhanced TIMELESS 
expression leads to a poorer prognosis in many cancers as well. Since there is less literature on 
the role of TIMELESS in colon cancer, and given its strong KSR1-like function, we sought to 





Figure 3.1: TIMELESS is overexpressed in colon cancer and CRC cell lines. (A) TIMELESS 
gene expression (RNA-Seq) data were analyzed from TCGA for unpaired primary colon tumors 
(n=285) and normal adjacent tissue (n=41) samples. These results are based on data generated by 
TCGA Research Network. Timeless protein (B) and mRNA (C) expression were evaluated by 
Western blot or RT-qPCR analysis, respectively. A panel of colon cancer cell lines were 
compared to HCECs. These data are representative of at least two independent experiments. *** 






Figure 3.2: TIMELESS expression has a dysregulated circadian rhythm in HCT116 cells. 
TIMELESS protein expression was evaluated over 24-hours following circadian synchronization 
achieved by serum shock (S.S.). (A) HCEC cells were collected every 6 hours and (B) HCT116 
cells were collected every 4 hours for 24 hours. Immunoblot of TIMELESS was used to evaluate 
expression and tubulin serves as a loading control. These data are representative of at least two 












TIMELESS was identified in the FUSION screen as being functionally related to KSR1. 
KSR1 is highly upregulated in colon cancer cells112. We began our analysis by searching The 
Cancer Genome Atlas (TCGA) dataset. This dataset provides RNA-sequencing data on several 
patient tumors and normal tissues. Upon our search for TIMELESS mRNA, we analyzed 41 
normal colon tissue and 285 unmatched colon tumors. The results show that colon 
adenocarcinomas have a 2.2-fold increase in TIMELESS mRNA compared to unmatched normal  
tissue (Figure 3.1A). Similar to the data suggesting overexpression of KSR1 protein and mRNA 
in colon cancer cells compared with non-transformed cells, we identified the same results for 
TIMELESS. In a panel of colon cancer cell lines, TIMELESS was significantly upregulated both 
at the protein and mRNA levels (Figure 3.1B-C).  
Because of the prominent circadian role of TIMELESS, we wanted to understand how 
this role differed in colon cancer compared to normal cells. To do this, we synchronized HCT116 
and HCEC cells to ensure that the circadian rhythm of all the cells was aligned. Then we 
collected cells at various timepoints over a 24-hour period to analyze TIMELESS protein 
expression. In HCECs, we found that TIMELESS protein expression exists in a classic circadian 
fashion with the height of the expression falling between 12- and 18-hours post-synchronization 
(Figure 3.2A). However, in HCT116 cells, TIMELESS protein expression is constitutively 
present at all time points evaluated in the 24-hour cycle (Figure 3.2B). These data suggest that 
there is dysfunction in the circadian rhythm, specifically through TIMELESS protein expression, 
of colon cancer cells compared to normal cells.  
To understand the role of TIMELESS in enhancing survival and viability of colon cancer 
cells compared to that of normal cells, we knocked down TIMELESS in both HCECs and 
HCT116 cells by RNAi. An immunoblot of PARP showed that in HCECs there was a decrease in 
total PARP following TIMELESS depletion in HCECs. However, in HCT116 cells, TIMELESS 





Figure 3.3: TIMELESS expression is necessary for colon cancer cell viability and 
proliferation but is dispensable to HCECs. (A) Immunoblot of PARP and γH2AX in HCECs 
and HCT116 cells was evaluated with or without TIMELESS knockdown. (B) AlamarBlue 
reagent was added to HCEC and HCT116 cells with or without TIMELESS knockdown to 
determine cell viability. Fluorescence of AlamarBlue was measured at 0 hour and 72 hours for 
each sample. (C) HCT116 cells were treated with CFSE while undergoing TIMELESS 
knockdown. Flow cytometry with curves representing the control (gray) and TIMELESS 
knockdown (black) cells (left) and quantification (right) are presented here. **** = p<0.0001. 
These data are representative of at least three independent experiments. A portion of these data 








Similarly, the knockdown of TIMELESS in HCECs and HCT116 caused an increase in 
γH2AX protein expression (Figure 3.3A). These data show that in normal cells, there is a slight 
increase in DNA damage following TIMELESS depletion, and in HCT116 cells the DNA damage 
induced by TIMELESS depletion enhances apoptosis.  
A cell viability assay was conducted to understand the differential effect of TIMELESS 
knockdown on HCECs or HCT116 cells using AlamarBlue stain. In HCECs, there was no change 
in AlamarBlue fluorescence following knockdown of TIMELESS. However, in HCT116 cells, 
there was a nearly 2-fold decrease in AlamarBlue fluorescence after knocking down TIMELESS  
(Figure 3.3B). These data show that cell viability is decreased in colon cancer cells following 
TIMELESS depletion but normal cells remain viable.  
The doubling rate of colon cancer cells following TIMELESS depletion was evaluated 
using CFSE stain. The CFSE stain is diluted during each cell doubling so a decrease in CFSE 
stain implies ample proliferation. In control HCT116 cells, there is 2.3-fold less CFSE stain 
compared to the cells with TIMELESS knockdown (Figure 3.3C). These data suggest that there is 
a significant decrease of cellular doubling in colon cancer cells depleted of TIMELESS compared 
to wild type cells.  
Next, we sought to further understand the mechanism behind the role of TIMELESS in 
colon cancer cells. Given a prominent role of TIMELESS has been shown to play in DNA 
damage and cell cycle regulation, a panel of colon cancer cells were treated with propidium 
iodide (PI) stain to analyze the cell cycle phase. HCT116, RKO, SW620, SW480, and HCT15 
cells with and without TIMELESS knockdown were treated with PI stain and analyzed by flow 
cytometry to determine the percentage of cells in sub-G1, G1, S, or G2 cell cycle phase (Figure 
3.4). The cell lines with TIMELESS knockdown showed a minimal increase in sub-G1 phase 
suggesting that there is only a small portion, if any, of the cells in a state of death. The percentage 
of cells in G1-phase is slightly decreased in TIMELESS knockdown cells compared to the 






Figure 3.4: TIMELESS depletion causes a G2/M arrest in colon cancer cell lines. (A) The 
percent of cells in sub-G1, G1, S or G2 phase in HCT116, RKO, SW620, SW480, and HCT15 
colon cancer cells with or without TIMELESS knockdown was quantified. Apoptotic cells and 
each phase of the cell cycle were analyzed by staining cells with propidium iodide and evaluated 
using flow cytometry. (B) Representative cell cycle histograms are also displayed. N=3. * = 
p<0.05, ** = p<0.01, *** = p<0.001, **** = p<0.0001. These data are a summary of one 






phase following TIMELESS knockdown compared to the control. Lastly, there was a significant 
increase in percentage of cells in G2-phase after TIMELESS knockdown compared to the control 
in all cell lines. The mechanism of TIMELESS to induce cell cycle arrest is shown to be a CHK1-
mediated event. The panel of colon cancer cells used in Figure 3.4 was further analyzed by 
Western blot (Figure 3.5). TIMELESS knockdown in these cells results in an increase in γH2AX 
compared to the respective control. There is also an increase in phosphorylated CHK1 at serine 
345 following TIMELESS depletion compared to the control cells. Lastly, there is an increase in 
phosphorylation of CDK1 at tyrosine 15 following TIMELESS knockdown. Overall, the changes 
seen in the phosphorylation of CHK1 and phosphorylation of CDK1 along with an increase of 
cells present in the G2 phase, suggest a G2/M arrest of colon cancer cells following TIMELESS 
depletion compared to control cells. 
The mechanisms regulating TIMELESS in colon cancer cells are not understood. Given 
that we originally identified TIMELESS to be functionally similar to KSR1, we began by testing 
if KSR1 was driving its expression. Following knockdown of KSR1, we did not see a decrease in 
TIMELESS protein (Figure 3.6A). This was not surprising given the parameters of the FUSION 
screen were to identify hits that are functionally similar to KSR1, not necessarily downstream 
effectors of KSR1, so we examined other potential regulatory pathways. Since Ras is mutated in 
the colon cancer cells, we obtained HCEC cells expressing activated RasG12V to investigate a 
differential expression of TIMELESS compared to the wild type HCECs. HCECs + RasG12V show 
a stabilization of TIMELESS in the circadian rhythm compared to wild type HCEC cells (Figure 
3.6B). These data are in contrast to the results observed in Figure 3.2A in which TIMELESS 
expression is only enhanced at hours 12 and 18 following synchronization.  
Since there are many signaling axes promoted by oncogenic Ras, we wanted to 
understand the specific signaling pathway affecting TIMELESS expression. KSR1 is a molecular 






Figure 3.5: TIMELESS knockdown induces cell cycle arrest through phosphorylation of 
CHK1 and subsequent inactivation of CDK1. Western blot analysis was conducted of 
phosphorylated and total H2AX, phosphorylated S345 and total CHK1, phosphorylated Y15 and 
total CDK1 in HCT116, HCT15, SW480, SW620, and RKO cells with or without TIMELESS 
knockdown. These data are representative of at least two independent experiments. A portion of 










Ras. We examined ERK as a potential regulator of TIMELESS. To begin investigating this, we 
knocked down ERK1/2 in HCT116 and SW480 cells. Western blot analysis showed a robust 
decrease of total ERK following ERK knockdown with a marginal decrease in TIMELESS 
protein expression (Figure 3.7A). Potent ERK inhibitor, SCH772984 (Erki), was used in a panel 
of colon cancer cells to evaluate TIMELESS protein expression. The ERK inhibitor effectively 
diminished TIMELESS protein expression in HCT116, CaCo2, and Sk-Co-1 cells, but not in 
HCT15 and FET cells (Figure 3.7B). Using HCECs with and without oncogenic Ras, the ERK 
inhibitor was added to the cells and Western blot analysis was used to assess TIMELESS protein 
expression. While control HCECs showed little to no expression of TIMELESS while there was 
an increase in TIMELESS expression in HCECs upon expression of oncogenic Ras (Figure 
3.7C). The ERK inhibitor was added to HCECs+Ras and complete ablation of TIMELESS 
protein expression was observed. 
We hypothesized that ERK regulates TIMELESS expression at the  
transcriptional level. However, RT-qPCR analysis of HCT116 cells with and without treatment 
with the ERK inhibitor showed no change in TIMELESS mRNA (Figure 3.8A). To determine if 
ERK inhibition affects translation of TIMELESS mRNA, we isolated the polysomes from 
HCT116 cells with and without ERK inhibitor treatment by centrifugation in a sucrose gradient. 
RT-qPCR of the polysome-bound mRNA showed approximately a 50% decrease in TIMELESS 
mRNA associated with polysomes following treatment with the ERK inhibitor (Figure 3.8B). The 
ratio of polysome-bound mRNA to total mRNA was defined as the Translational Efficiency. Our 
data shows that the translational efficiency of TIMELESS mRNA was much lower in ERK 
inhibited cells compared to the control (Figure 3.8C). Taken together, these data show the 
importance of TIMELESS in colon cancer cell survival and growth. TIMELESS, which is 
enhanced by ERK, inhibits DNA damage in colon cancer cells, which bypasses cell cycle arrest. 
This is in contrast to the function of TIMELESS in HCECs, where TIMELESS expression is 







Figure 3.6: Oncogenic Ras, but not KSR1, drive aberrant protein expression of TIMELESS 
protein. (A) KSR1 and TIMELESS protein expression in HCT116 cells with or without KSR1 
knockdown was determined by immunoblot analysis. These data are a summary of one 
experiment.  (B) The circadian pattern of TIMELESS protein expression was analyzed in HCECs 
with addition of oncogenic Ras. Cells were collected every four hours following serum shock 
synchronization, up to 24 hours. Wild type HCECs were collected at 16 hours following serum 
shock synchronization. These data are representative of at least two independent experiments. 














Conclusions and Discussion 
To identify functionally similar proteins, a Function Signature Ontology (FUSION) 
screen was performed. Following the screen, extensive bioinformatic analysis was performed to 
identify proteins that are functionally similar to KSR1. While many genes and pathways were 
identified through analysis of the FUSION screen, one main set of genes most significantly 
shown to be functionally similar were circadian rhythm genes, specifically, a lesser-known 
circadian rhythm gene called TIMELESS. 
These results demonstrate that oncogenic Ras activation mediated by ERK, but independent of 
KSR1, enhances TIMELESS circadian expression translationally in colon cancer cells through 
mediation of ERK. Colon cancer cell proliferation is dependent upon TIMELESS expression and 
this can be attributed, at least in part, to TIMELESS depleted cells undergoing a G2/M cell cycle 
arrest. This arrest in cell cycle progression was further characterized by an increase in CHK1 
phosphorylation with subsequent inactivation of CDK1 following DNA damage as measured by 
γH2AX.  
TIMELESS is necessary for viability in colon cancer cells but dispensable for non-
transformed cells. However, cell cycle analysis suggests that there are very few apoptotic cells. 
This is in contrast to the Western blot analysis showing an increase in cleaved PARP following 
TIMELESS depletion. This may be an effect of TIMELESS interacting with PARP307, which 
could mean the cleaved PARP Western blot may be misleading since PARP expression may be 
increased because its binding partner, TIMELESS, is no longer available for sequestering it. 
Future work should examine the mechanisms through which TIMELESS promotes cancer cell 
survival. 
Multiple studies have shown that multiple cancers overexpress TIMELESS311,313,314,317-319. 
However, the mechanism of TIMELESS overexpression is largely tumor-type dependent. In 
colon cancer cells, we observed TIMELESS expression mediated by ERK signaling downstream 





Figure 3.7: ERK mediates TIMELESS expression. (A) TIMELESS and total ERK protein 
expression in HCT116 and SW480 cells with or without ERK knockdown was determined by 
immunoblot analysis. (B) Western blot analysis was performed on lysates of HCT116, CaCo2, 
HCT15, Sk-Co-1, and FET colon cancer cells with or without treatment of SCH772984 (Erki). 
(C) HCECs with or without addition of oncogenic Ras were evaluated by Western blot for 
TIMELESS protein expression with or without treatment of SCH772984. These data are 
representative of at least three independent experiments. A portion of these data were completed 












levels, ERK knockdown showed a minimal decrease in TIMELESS expression compared to ERK 
inhibitor SCH772984. One explanation for these results could be the length of the two 
experiments. A transient transfection is typically completed after 72 hours, whereas treatment 
with the ERK inhibitor is completed after 24-48 hours. However, the fact that ERK protein 
expression is still depleted in the transient knockdown suggests that the mechanism should still be 
shut down. However, cell confluency following the length of these experiments could cause a 
more minimal decrease in TIMELESS protein while showing complete knockdown of ERK. 
Alternatively, the effect of SCH772984 on TIMELESS may be off target. Additional experiments 
with other inhibitors of Raf/MEK/ERK kinase cascade should clarify these disparate results. 
ERK inhibitor SCH772984 affects only a subset of the colon cancer cell lines tested. 
HCT15 and FET cells did not show a decrease in TIMELESS protein expression following  
treatment with the ERK inhibitor. HCT15 cells harbor a PI3K and TP53 mutations not detected in 
the other cell lines, which may account for differential effects seen with the ERK inhibitor since 
ERK is only one oncogenic driver. We subsequently determined that HCT15 cells were more 
sensitive to mTOR inhibition (data not shown) while the mutational profile of the FET cells is not 
well characterized. HCT15 cells did show the same mechanism of increased γH2AX with 
activation of CHK1 and inactivation of CDK1 following TIMELESS depletion. It is shown that 
HCT15 cells have a high basal level of phosphorylated CDK1, suggesting that these cells may 
have additional alterations.  
Given that other cancer types have distinct mechanisms to upregulate TIMELESS, it is 
plausible that there is more than one mechanism in colon cancer. The promoter region on the 
TIMELESS gene contains an E-box sequence that drives circadian rhythm transcription factors. 
The proto-oncogene, Myc, has been shown to bind E-box motifs, leading to the possibility that 
TIMELESS could be driven by Myc, a proto-oncogene, as well. Since we have shown that Ras 





Figure 3.8: Translation efficiency of TIMELESS is regulated by ERK in HCT116 cells. 
Total mRNA, polysome-bound mRNA and Translational efficiency (TE) of TIMELESS mRNA 
was evaluated in HCT116 following ERK inhibition with 1μM SCH772984. (n=3). These data 
are a summary of one experiment. These data were completed in collaboration with Eyerusalem 

















plausible that either MYC or ERK could be intermediary regulators of TIMELESS. Similarly, 
future work should investigate the post-translational modifications and localization of 
TIMELESS in colon cancer. For example, assessing the nuclear localization and phosphorylation 
status of TIMELESS may explain the over activation of TIMELESS protein in colon cancer cells, 
whereas these characteristics may not be present in normal cells.  
ERK inhibition does not affect total TIMELESS mRNA so the ability of ERK to initiate 
translation of TIMELESS was evaluated. We performed RT-qPCR for TIMELESS mRNA bound 
to polysomes. ERK inhibitor SCH772984 significantly decreased the amount of polysome-bound 
TIMELESS mRNA. These data suggest that the cancer cells preferentially translate TIMELESS 
to enhance survival and override DNA damage. 
Given that the cancer cells require TIMELESS expression for robust proliferation and 
survival and HCECs do not contain a constitutve level of TIMELESS protein expression, makes 
it a reasonable therapeutic target. It may be beneficial to target TIMELESS in combination with 
other DNA damaging therapeutics. If synergistic, the large accumulation of DNA damage and 
limited repair capacity may lead to cancer cell death. This may also suggest that 
chemotherapeutics dosed in a circadian manner may be more effective. For example, if 
chemotherapeutics were administered when TIMELESS expression was low in normal cells, but 
constitutively high in cancer cells, it may cause less toxicity to patients. 
Another way to target TIMELESS may be through PARP inhibitors, which trap 
TIMELESS at the site of DNA damage307 and prevents TIMELESS from functioning normally. 
TIMELESS has not been evaluated in this context, and a much higher dose of PARP inhibitor 
may be necessary to counteract the high levels of TIMELESS in cancer. This also provides a 
rationale for future efforts to develop a specific and robust inhibitor of TIMELESS. Overall, the 
data presented here demonstrate a role for TIMELESS in cancer and suggest further examination 
of the link between the circadian rhythm and cell cycle. In normal cells the circadian rhythm 
































PGC1 proteins dictate the transcriptional activity of ERR proteins211,212,320-323. The three 
LXXLL motifs encoded within PGC1 proteins act as docking sites for nuclear receptors, though 
the more atypical L3 motif has a high affinity for ERR proteins 212,238,324,325. Similarly, PGC1 
expression can be stimulated physiologically through exercise, fast, and other processes that drive 
oxidative stress. ERR proteins act as monomers due to half sites of consensus found in many 
mitochondrial genes, they are not thought to be stimulated by ligands but instead they require a 
coactivator 201  These observations reveal a functional codependency between PGC1 and ERR 
proteins in their ability to express target genes that regulate mitochondrial biogenesis, energy 
homeostasis, and glucose metabolism211,214,245,326,327. Although studies have focused on the target 
genes of ERR𝛼 in breast cancer237,328, the results appear to be context dependent and potentially 
independent of the PGC1 coactivator. Similarly, no studies have been done to evaluate the 
downstream targets of the PGC1-ERR signaling axis in colon cancer, despite highly upregulated 
PGC1𝛽 and ERR𝛼 protein and mRNA expression in several colon cancer cell lines and tissue 
samples112. Although many studies focus on the function of PGC1α, it is clear PGC1𝛽 plays a 
vital role in metabolic regulation. PGC1𝛽 recruitment was seen at genomic sites occupied by 
ERR𝛼 and PGC1𝛽 knockdown shows a decrease in ERR𝛼 target gene expression237,328. The 
decrease in PGC1𝛽, and subsequently ERR𝛼, expression leads to a decrease in cell growth329,330 
suggesting a vital role played by both PGC1𝛽 and ERR𝛼.  
To understand the role of both PGC1𝛽 and ERR𝛼 in colon cancer, we sought to 
investigate the metabolic effects following the depletion of PGC1𝛽 signaling. Similarly, our 
group performed an unbiased RNA-sequencing experiment following the knockdown of either 
PGC1𝛽 or ERR𝛼 in colon cancer cells. Our studies aimed to determine the specific role(s) of 






Figure 4.1 PGC1𝛽 expression is vital to maintain oxidative phosphorylation in colon cancer 
cells: (A) HCT116 cells, (B) T84 cells, or (C) SW480 cells were treated with either PGC1𝛽-
targeted or non-targeted siRNA. Oxygen Consumption Rate (OCR, pmol oxygen per minute) was 
measured over time. Oligomycin, FCCP, rotenone were added at the indicated timepoints. These 











 PGC1𝛽 was knocked down in three colon cancer cell lines, HCT116, T84, and SW480. 
The cells were plated in a 96-well microplate compatible with the XFe96 Seahorse machine. 
An hour before the experiment, all medium was replaced with sodium bicarbonate-free medium 
containing only DMEM, glucose, glutamine, and sodium pyruvate as described in Materials and 
Methods. This medium change minimized the influence of culture medium or residual 
metabolites on oxygen consumption or acidification rate measurements. Cells were placed in an 
incubator with ambient oxygen at 37ºC. Background oxygen is subtracted from the samples, so 
we ensure that the only oxygen measurement is generated by the cells. After calibration of the 
probes in the calibration medium that is also incubated in ambient oxygen at 37ºC, the cells were 
placed into the Seahorse chamber. First, five baseline measurements of oxygen consumption rate 
were taken every three minutes. Next, a series of three drugs were added and three measurements 
of oxygen consumption were taken every three minutes after a mixing step. Oligomycin was 
added first to inhibit Complex IV of the electron transport chain. In this case, we would expect 
the oxygen consumption rate to drop because oxidative phosphorylation has decreased. This drop 
exhibits the amount of ATP-linked respiration that was occurring in the cells. Then, FCCP 
(Carbonyl cyanide-4-(trifluoromethoxy)penylhydrazone) was injected into the cells. FCCP is a 
protonophore mitochondrial uncoupler that collapses the inner mitochondrial membrane gradient 
and allows hydrogen ions to flow freely throughout the mitochondrial membrane. In cancer cells, 
we expect to see an increase of oxygen consumption, at least to the level of the baseline 
measurements. This is because cancer cells are typically performing at their maximum respiratory 
rate so the addition of FCCP should allow the cells to resume their baseline respiration. In 
HCECs, after the addition of FCCP, we expect to see an increase above their baseline rate. Lastly, 
rotenone is injected into the cells to inhibit Complex I of the electron transport chain. Inhibition 
of Complex I effectively halt all oxygen consumption of the electron transport chain and 





 These data give the overall OXPHOS profile of the CRC cells with and without PGC1𝛽 
knockdown. In HCT116 cells, the curve is shifted significantly lower in the presence of PGC1𝛽 
siRNA (Figure 4.1A). However, upon addition of oligomycin and rotenone, the control values 
match the values seen with PGC1𝛽 knockdown. In T84 (Figure 4.1B) and SW480 (Figure 4.1C) 
cells, the overall oxygen consumption rate is lower in the PGC1𝛽 knockdown cells compared to 
that of the control cells. The data shown here confirms that OXPHOS processes are significantly 
impaired when PGC1𝛽 is knocked down in CRC cell lines. 
 Measurements of baseline OCR and maximal respiratory rate were quantified. Baseline 
OCR (Figure 4.2A) was calculated by subtracting the OCR values following rotenone treatment 
from the baseline OCR measurements. In HCT116 cells, baseline OCR values were decreased by 
2.25-fold with PGC1𝛽 depletion. In T84 cells, baseline OCR was decreased by 1.57-fold with 
PGC1𝛽 knockdown. Similarly, SW480 cells had a 1.58-fold decrease in baseline OCR following 
PGC1𝛽 knockdown. Maximal respiratory rate (Figure 4.2B) was calculated by subtracting the 
OCR values following rotenone treatment from the OCR values following FCCP addition. In 
HCT116 cells, maximal respiratory rate was decreased by 1.90-fold following PGC1𝛽 
knockdown. In T84 cells, maximal respiratory rate was decreased by 1.51-fold following PGC1𝛽 
knockdown. Lastly, SW480 cells had a decrease in maximal respiratory rate by 2.01-fold 
following PGC1𝛽 knockdown. Overall, these data suggest that the oxygen consumption rate, and 
effectively OXPHOS, is significantly decreased following PGC1𝛽 depletion in CRC cell lines.  
Effects on glycolysis were also evaluated following PGC1𝛽 depletion. This was done by 
the ability of the XFe96 Seahorse to measure the pH of the medium following the addition of 
three drugs. As glycolysis occurs, lactate is a byproduct. Lactate enhances the acidity of the 
medium; therefore, the measurement of extracellular acidification rate (ECAR) is used as a 





Figure 4.2 PGC1𝛽 expression is vital to maintain Baseline OCR and Maximal Respiratory 
Rate: (A) Baseline OCR was measured by averaging the first five measurements of three 
technical replicates for either HCT116, T84, or SW480 cells. Control (black bars, n = 15) values 
are normalized to 1 and PGC1𝛽 knockdown (gray bars n = 15) values are compared to control 
using a Student’s t-test. (B) Maximal Respiratory Response was calculated by averaging the 
difference between the OCR values following the addition of FCCP and the OCR values 
following the addition of Rotenone. These data are representative of at least two independent 


































































Figure 4.3: PGC1𝛽 expression is vital to maintain glycolysis in colon cancer cells. 
Extracellular Acidification Rate (ECAR, mpH per minute) was measured in (A) HCT116 cells or 
(B) T84 cells treated with PGC1𝛽-targeted or non-targeting siRNA. The metabolic profile was 
analyzed over time following the addition of glucose, oligomycin, and 2-DG at the indicated time 























Figure 4.4: PGC1𝛽 expression is vital to maintain glycolysis and glycolytic capacity in colon 
cancer cells. (A) Glycolysis was measured by averaging the difference between the ECAR values 
following the addition of glucose and the ECAR values following the addition of 2-DG. Controls 
(black bars, n = 9) were normalized to 1 and PGC1𝛽 knockdown samples (gray bars, n = 9) were 
compared to the control using Student’s t-test. (B) Glycolytic capacity was measured by 
averaging the difference between ECAR values following the addition of oligomycin and the 
ECAR values following the addition of 2-DG. Controls (black bars, n = 9) were normalized to 1 
and PGC1𝛽 knockdown samples (gray bars, n = 9) were compared to control using Student’s t-
test.  These data are representative of at least two independent experiments. *** = p-value < 






cells to feed the glycolysis pathway. The colon cancer cells without PGC1𝛽 expression decrease 
their ability to perform glycolysis by approximately half, even after the addition of ample 
substrate, compared to the control cells (Figure 4.4A). Next, oligomycin was added to the cells. 
As previously mentioned, oligomycin inhibits ATP to be synthesized from the electron transport 
chain. After the addition of oligomycin, glycolysis is the main process by which the cells generate 
energy. ECAR readings following oligomycin addition reflect the cells glycolytic capacity. In 
HCT116 cells without PGC1𝛽, the glycolytic capacity is decreased by approximately half 
compared to the control (Figure 4.4B). In T84 cells without PGC1𝛽, the glycolytic capacity is 
decreased by approximately 75% compared to the control (Figure 4.4B). 2-DG was added to the 
cells to competitively inhibit the production of glucose-6-phosphate from glucose; blocking the 
second step of glycolysis resulted in significant decrease in ECAR measurements, as expected. 
Protein quantification analysis was performed in the T84 cells and each measurement was 
normalized to protein levels.  
Given the prominent effect of PGC1𝛽 and ERR𝛼 on metabolic processes in colon cancer 
cells, we sought to define specific downstream effectors of both PGC1𝛽 and ERR𝛼. This 
rationale was amplified by the lack of clinically relevant inhibitors of either PGC1𝛽 or ERR𝛼. 
HCT116 cells were transfected with two independent siRNA targeting either PGC1𝛽 or ERR𝛼 in 
comparison with non-targeting control oligos. Each condition was tested in biological triplicate 
with two separate oligos for each target. The mRNA was isolated from each sample and RNA-
sequencing was performed. Following deSeq2 analysis of the data, the genes were ranked in 
descending order by p-value (Table 1). As seen previously, PGC1𝛽 and ERR𝛼 enhance metabolic 
processes, so it was not surprising that many metabolic genes were altered in common with 
PGC1𝛽 and ERR𝛼 knockdown. We were particularly interested in the statistically significant 
upregulated or downregulated genes in common with both PGC1𝛽 and ERR𝛼	knockdown 





Table 1: Genes altered in HCT116 cells following knockdown of PGC1𝛽 or ERR𝛼 




siPGC1!  siERR"  








ESRRA -3.0501725 4.34E-23 SLC1A4 -3.8956646 2.63E-12 
PCK2 -2.9644106 2.35E-13 PCK2 -3.9065517 5.96E-12 
SLC1A4 -2.7414698 2.65E-12 JDP2 -2.8422453 2.00E-10 
TRIB3 -1.82452 1.82E-08 LMNB1 -2.6485427 2.40E-10 
PSAT1 -1.6115383 2.54E-08 CHAC1 -2.91747 6.56E-08 
DDIT4 -2.0444729 4.67E-08 C1orf116 2.80287776 7.74E-08 
CPA4 1.76323906 7.60E-08 HR -2.0447284 4.57E-07 
GPT2 -1.6992819 1.01E-07 MDK -1.7412193 1.17E-06 
ULBP1 -1.9837393 2.01E-07 NRP1 2.87549936 4.34E-06 
ASNS -2.4863819 4.64E-07 TFPI 1.87366954 4.55E-06 
JDP2 -1.9716087 7.61E-07 PHGDH -2.3778323 5.27E-06 
IL6R 1.48849468 1.09E-06 FHL1 -2.6007623 9.10E-06 
SEMA7A 1.73161535 1.17E-06 ASNS -2.2820422 2.43E-05 
KRT80 2.30875312 1.00E-05 CPA4 2.25251952 4.07E-05 
NR6A1 1.70161587 1.18E-05 ZBTB20 2.25834811 8.26E-05 
BIRC3 2.1938021 2.89E-05 CEACAM1 3.14424259 8.58E-05 
SLC43A1 -2.8855272 3.52E-05 LMO7 2.19563308 8.58E-05 
AMMECR1 1.19063512 3.58E-05 PALM3 -3.4196186 0.00010345 
PDGFB 1.7233171 3.98E-05 AMPD3 1.65302827 0.00010467 
LRATD2 -1.2124766 4.54E-05 SNAI2 3.16959983 0.0001191 
PHGDH -1.4993388 0.00013067 PSIP1 -1.7414462 0.0001191 
STC2 -1.150869 0.00015699 BTG2 1.95825153 0.0001312 
KCNH3 -1.6289723 0.00015699 KDM5B 1.50327189 0.00013924 
NACC2 1.08933939 0.00015699 NUP210 -1.841356 0.00013924 
SH3RF2 1.81821689 0.00036751 DOCK4 1.72009796 0.00014812 
SOCS1 2.24381519 0.00036751 EIF5A2 -1.8039583 0.00014812 
ANKRD52 1.32571374 0.00037372 COL17A1 2.60487877 0.0001486 
PDCD4 -1.5262688 0.00053679 GPT2 -1.7892692 0.00014877 
KRT23 -1.5967489 0.00061723 ZNF367 -2.5428911 0.00015907 





ERR𝛼 knockdown would enhance tumor growth. Knockdown of either PGC1𝛽 or ERR𝛼 
significantly increased the gene AMMECR1. In lung cancer cells, AMMECR1 inhibits apoptosis, 
promotes cell cycle progression, and increases colony formation331. Low expression of BIRC3, a 
gene that is also upregulated with PGC1𝛽 or ERR𝛼 depletion, dictates CLL disease progression 
since it is shown to decrease apoptosis332,333. In contrast, overexpression of CPA4 is supportive of 
NSCLC and breast cancer growth and sruvival334-336. LAMB3 and LAMC2 have also been shown 
to enhance tumor growth by regulating apoptosis and EMT processes337,338. NAV3, a modulator 
of cell migration, was found to be deleted in 30% of colorectal carcinomas and 23% of colorectal 
adenomas. Similarly, NAV3 inhibition enhances breast cancer progression339,340.  Neuropilin-1 
has been shown to be upregulated in CRC cells compared to normal mucosa and confers 
resistance to inhibitors targeting oncogenes341,342. PLK2, a target of p53, is commonly seen 
downregulated in colorectal carcinomas, but not adenomas, and enhances mTOR signaling343.  
Overexpression of SEMA7A can drive metastatic breast and oral cancer344,345. Lastly, inactivation 
of WNT9A, a non-canonical WNT pathway ligand, has been shown to enhance human CRC 
proliferation through a decrease in apoptosis and increase in 𝛽-Catenin protein346. No previous 
literature has studied these proteins in correlation with PGC1𝛽 or ERR𝛼.  
In order to reveal the proteins positively correlated with PGC1𝛽 and ERR𝛼 signaling, we 
examined the significant downregulated genes in common with both PGC1𝛽 and ERR𝛼 
knockdown. These genes included MTHFD2, PHGDH, and PSAT1 that cluster with the serine 
synthesis pathway. Similarly, ASNS, GPT2, OGDHL, and ASCT1 (SLC1A4) clustered with 
glutaminolysis and the TCA cycle.  
MTHFD2 is a mitochondrial one-carbon folate metabolic enzyme that is required for 
cancer cell proliferation and decreasing the expression of MTHFD2 could impair aggressive 
cancer phenotypes347-352.PHGDH is required to maintain nucleotide synthesis through support of 





Table 2: Genes significantly upregulated or downregulated in HCT116 cells following 














Genes Increased Genes Decreased 
Gene siPGC1!    
Fold Change 
siERR"         
Fold Change 
Gene siPGC1!    
Fold Change 
siERR"         
Fold Change 
AMMECR1 1.19063512 1.44036653 ASNS -2.4863819 -2.2820422 
BIRC3 2.1938021 1.78779882 CRNDE -1.4728294 -1.7401418 
CPA4 1.76323906 2.25251952 GPT2 -1.6992819 -1.7892692 
LAMB3 1.27571156 1.59844966 JDP2 -1.9716087 -2.8422453 
LAMC2 1.16106318 1.34090028 MTHFD2 -0.8995022 -1.4085796 
NAV3 1.30939327 1.51519503 NIBAN1 -1.8512947 -2.6020697 
NRP1 1.76323906 2.87549936 OGDHL -2.0294508 -2.9828789 
PLK2 1.46404056 2.06091798 PCK2 -2.9644106 -3.9065517 
SEMA7A 1.73161535 1.63870558 PHGDH -1.4993388 -2.3778323 
WNT9A 1.60942304 1.86051966 PSAT1 -1.6115383 -2.0074147 
   SLC1A4 -2.7414698 -3.8956646 
   SLC43A1 -2.8855272 -2.5082388 





PHGDH activity is also associated with increased breast cancer risk354. PSAT1 assists in serine 
synthesis and overexpression correlates with poor outcomes in lung cancer patients355,356. ASNS 
uses the substrate glutamine to synthesize asparagine which is then used for protein synthesis and 
regulates mTORC1 activation, promoting cancer progression. Amino acid-starvation-induced 
upregulation of ASNS is mediated by ATF4357,358. GPT2 generates pyruvate  
and glutamate with increased expression in breast cancer and supports tumorigenesis through 
activation of hedgehog signaling359,360. Conversely, OGDHL expression is decreased in several 
cancers and is a negative prognostic biomarker for lung cancer361-364. ASCT1 is a neutral amino 
acid transporter and has no known role in cancer. There is currently no literature linking PGC1𝛽	
or	ERR𝛼 with any of the downregulated genes discussed. 
In addition to specific gene regulation, we also analyzed the pathways significantly 
downregulated by PGC1𝛽 or ERR𝛼 knockdown (Figure 4.5). Using GSEA, a comparison of 
pathways was done, and a clustering method was applied. Many metabolic pathways were 
downregulated including Amino Acid Metabolism, Pentose Phosphate Pathway, and Pyruvate 
Metabolism. As previous data has shown (Table 2), genes associated with Oxidative 
Phosphorylation were significantly decreased in PGC1𝛽 and ERR𝛼 knockdown cells. Similarly, 
the most significant downregulated pathways include the TCA Cycle and Glyoxylate and 
Carboxylate Metabolism.  
 
Conclusions and Discussion 
 PGC1𝛽 and ERR𝛼 have been shown to promote cellular bioenergetics in many models. 
In colon cancer, the PGC1𝛽-ERR𝛼 signaling axis enhances metabolic processes to support 
increased cell growth. These data show that both glycolysis and oxidative phosphorylation are 
significantly decreased with PGC1𝛽 knockdown in CRC cell lines. This suggests that PGC1𝛽 







Figure 4.5 GSEA analysis of a subset of significant KEGG pathways downregulated with 











results led to the question of which genes are being promoted by PGC1𝛽, and subsequently 
ERR𝛼, to understand the specific mechanism that makes this signaling axis vital to cancer cell 
metabolism. Previous literature largely focuses on downstream ERR𝛼 targets that ultimately lead 
to increased metabolic processes. However, these data do not include the targets of PGC1𝛽, the 
main coactivator of ERR𝛼, and were not done in CRC cells. Based on RNA sequencing 
performed, many genes were significantly upregulated or downregulated following either PGC1𝛽 
or ERR𝛼 knockdown. Many of the genes upregulated following PGC1𝛽 or ERR𝛼 knockdown 
have been shown to inhibit cancer cell growth. These data support the idea that PGC1𝛽 and 
ERR𝛼 are downregulating genes that inhibit cellular proliferation, ultimately increasing cancer 
growth. In contrast, a portion of the genes that were shown to be upregulated following PGC1𝛽 
and ERR𝛼 knockdown have literature suggesting they support cancer growth. This would be in 
contrast to previous data suggesting PGC1𝛽 and ERR𝛼 support cancer growth because PGC1𝛽 
and ERR𝛼 would be decreasing supportive genes. For example, LAMB3, LAMC2, and SEMA7A 
expression have been shown to increase tumor progression. Therefore, it is curious why PGC1𝛽 
and ERR𝛼 downregulate these genes in HCT116 cells. One possibility is that this is an effect of 
the HCT116 cells. Perhaps if the experiment were performed in a panel of CRC cell lines, the 
result would suggest a variable set of genes downregulated by PGC1𝛽 and ERR𝛼. Another 
explanation for the paradoxical downregulation of these genes could be that the cancer cells are 
employing a compensatory mechanism to support cell growth and survival in the absence of 
PGC1𝛽 and ERR𝛼. Since there is little literature on these genes in CRC, another possibility is 
that these genes have a different function in colon cancer than they do in other cancers.  
The genes that were altered by both PGC1𝛽	depletion and ERR𝛼 depletion were of 
particular interest because those are likely the genes regulated by PGC1𝛽 and ERR𝛼 to support 
cancer metabolism. Our data suggest that PGC1𝛽 and ERR𝛼 regulate genes that support cancer 




are many genes that are not in common with both PGC1𝛽 and ERR𝛼 knockdown. This would 
suggest independent roles of these two proteins. For example, PGC1𝛽 could co-activate other 
transcription factors through binding of the LXLL motif. This would result in gene activation 
separate of those activated by ERR𝛼. Similarly, ERR𝛼 may enhance gene expression independent 
of PGC1𝛽. This suggests that ERR𝛼 may potentially function independent of a co-activator or of 
a co-activator that is not PGC1𝛽. Through these studies, it is clear that the role of PGC1𝛽 and 
























Chapter 5: Nrf2 plays a central role in PGC1𝛽 signaling and 














ROS in Cancer 
 Many strategies to treat cancer, such as utilization of radiation and some 
chemotherapeutics, generate reactive oxygen species (ROS) to cause stress in the cancer cells and 
lead to genomic instability and decrease cellular defense 164,365,366. ROS plays an oscillating role in 
cancer because there must be a certain balance in order for the cancer cell to function optimally. 
Since ROS plays a role in cell cycle progression, proliferation, energy metabolism and survival, 
the level of ROS needs to be high enough to enhance these processes367-369. However, if the 
increase in ROS is too large, it can induce cell cycle arrest and apoptosis due to a release in 
cytochrome C370,371.  
This delicate balance of ROS is mediated by the antioxidant response system. This 
system is comprised of a transcription factor, Nuclear factor-erythroid-2-related factor 2 (Nrf2) 
and its repressor, Kelch-like ECH-associated protein 1 (Keap1)372-374. In normal conditions, Nrf2 
is bound to Keap1 in the cytoplasm and degraded by ubiquitination. In times of oxidative stress, 
Nrf2 is released from Keap1 through disruption of cysteine residues on Keap1 resulting in the 
stabilization of Nrf2. Following a build-up of Nrf2, it is translocated to the nucleus and 
transcribes genes containing an antioxidant response element (ARE) in the promoter region such 
as NQO1, HO-1, GCLC, and GST375-378. For the purposes of this project, NQO1 will be used as a 
readout of Nrf2 activation and signaling. NQO1 is an NAD(P)H quinone oxidoreductase that 
catalyzes the two-electron reduction of harmful, reactive quinones that cause oxidative stress379.  
 
Nrf2 background 
Nrf2 was originally identified in 1994 with a main function as a transcriptional 
stimulator380 and was later characterized to belong to the cap “n” collar family of basic leucine 




p45 subunit. Although there are similarities between the function of Nrf1 and Nrf2, Nrf1 is 
necessary for embryonic development and survival during development382,383, while Nrf2 
knockout mice develop normally. Similarly, Nrf3 may have functions comparable to those of 
Nrf1 and Nrf2 but specific studies have not been done though subcellular localization does not 
indicate similar mechanisms of action384,385.  
 Nrf2 has several Nrf2-ECH homology (Neh) domains within the protein structure. The 
Neh1 motif is necessary for DNA binding386. The Neh2 domain contains two motifs that are 
necessary to interact with the negative regulator, Keap1. Contained within this domain is a 
sequence of lysines that are targeted for ubiquitylation375,387. Neh3-5 motifs contain 
transactivation domains and Neh6 is necessary for Nrf2 stability, independent of its binding to 
Keap1. The stabilization of Nrf2 is more efficient following its phosphorylation by GSK3β388. 
Lastly, although Keap1 provides regulatory mechanism, Nrf2 is also regulated transcriptionally389 
through the Neh7 motif, which represses Nrf2 transcriptional activity by binding of RXRα390. 
 
Nrf2 signaling in cancer 
Given the delicate balance of oxidative stress necessary in cancer, Nrf2 signaling plays a 
vital role in cancer progression. There is significant evidence that Nrf2 activation inhibits 
tumorigenesis, especially in the early stages. One mechanism by which Nrf2 mitigates cancer risk 
is by protecting cells against inflammation-related injury, thus reducing carcinogenesis induced 
by inflammation391,392. Therefore, Nrf2 activators have been evaluated in clinical trials for cancer 
treatment. After the failure of many of these experimental treatments, it is now known that Nrf2 
signaling can also promote cancer growth and proliferation. It has been shown that oncogenes, 
such as K-Ras, B-Raf, and MYC suppress ROS by activating Nrf2 signaling. Mediators of 
oncogenesis through Nrf2 have been studied in pancreatic cancer and lung cancer176. Nrf2 
signaling also enhances metabolic enzymes and subsequent metabolic processes, such as the 




proliferation393,394. Nrf2 also modulates mRNA translation, a necessary process for cancer cell 
maintenance395. In times of oxidative stress, when ROS levels increase and threaten cancer cell 
death, Nrf2 signaling suppresses apoptosis by enhancing genes that scavenge ROS396. In early 
tumor stages, the decrease in inflammation induced by Nrf2 signaling can help mitigate the 
progression of cancer. However, in later staged cancers, the decrease in inflammation can 
catalyze proliferation and growth397. Lastly, Nrf2 signaling has been shown to confer 
chemoresistance in cancer cells. Certain chemotherapeutics activate Nrf2, allowing the cancer 
cells to combat apoptosis and stress induced by the drug. Specifically, Nrf2 depletion sensitizes 
colon cancer cells to cisplatin, melphalan, and etoposide398,399. 
 
Nrf2 inhibitors 
Overall, there is certainly a pro-tumor role of Nrf2 signaling. Although there are many 
potent Nrf2 activators, these may not be viable for more progressed tumors. However, the studies 
looking into Nrf2 inhibitors are controversial. Nrf2 activators often inhibit the interaction 
between Keap1 and Nrf2, making Nrf2 constitutively active. Development of Nrf2 inhibitors has 
not been as straightforward, given that Nrf2 is a generic basic leucine zipper. Similarly, Nrf2 is a 
transcription factor, which have been notoriously difficult to target effectively. Nrf2 knockout 
mice are still viable and have few defects, suggesting that it is a promising therapeutic target400. 
One way inhibitors of Nrf2 have been developed is by interfering with its transcriptional activity, 
preventing it from binding to the ARE motif of target genes390. Another opportunity for the 
development of inhibitors lies in natural compounds. While some compounds have been 
evaluated as effective, such as ascorbic acid and brusatol, their selectivity and mechanisms of 
action have not been conclusive401,402. High-throughput screening of compounds identified 
ML385 as a Nrf2 inhibitor, potentially through its interactions with the DNA-binding domain, 




















Figure 5.1: PGC1𝛽 and Nrf2 regulate mitochondria ROS in HCT116 cells. Mitochondrial 
ROS was measured by averaging the median fluorescence of MitoSox Red dye in HCT116 cells 
following PGC1𝛽 or Nrf2 transient knockdown for 72-hours compared to a non-targeting control. 







































Although it is clear that Nrf2 plays a prevalent role in cancer progression, there are many 
gaps in the literature leaving unexplained mechanisms and further questions. The mechanism by 
which Nrf2 reprograms metabolism to enhance tumor formation is unclear. Given the prominent 
role Nrf2 plays in ROS-scavenging, it is also unclear if it affects oxidative phosphorylation. 
Mitochondrial ROS produced by oxidative phosphorylation would lead to the assumption that the 
antioxidant response would be necessary to mitigate harmful superoxides produced through the 
electron transport chain. It is also unclear if Nrf2 transcribes the same genes under controlled 
activation as it does under constitutive or altered activation. Lastly, because of the difficulties in 
developing Nrf2 inhibitors, it is important to understand mechanisms used in the context of 
cancer to specifically inhibit downstream targets of Nrf2. 
 
Results 
Mitochondria are the main source of ROS, particularly due to the electron transport 
chain404,405. There are nearly a dozen sites where the mitochondria produce superoxide or 
hydrogen peroxide, specifically during the process of electron transfer in complex I160,406-408. 
Since PGC1𝛽 significantly effects oxidative phosphorylation and presumably the electron 
transport chain, we hypothesized that the detrimental effects to the cell following depletion of 
PGC1𝛽 may be due, in part, to increased ROS production. In order to test this, we measured 
mitochondrial ROS and normalized to total mitochondria staining. The results show that 
following PGC1𝛽 knockdown, mitochondrial ROS is increased approximately 5-fold (Figure 
5.1). In fact, PGC1𝛽 depletion increased ROS levels in a manner similar to that of Nrf2 depletion, 
a positive control as a master regulator of ROS scavengers.  These results led us to believe that 
there may be a relationship between PGC1𝛽 and Nrf2. Since PGC1𝛽 is a coactivator and Nrf2 is 
a transcription factor, our original hypothesis was that PGC1𝛽 regulates the transcriptional 
















Figure 5.2: Nrf2 regulates the expression of PGC1𝛽 and ERR𝛼 in HCT116 cells. 
Immunoblot analysis was performed on lysates of PGC1𝛽 or Nrf2 knockdown cells compared to 
a non-targeting control. HCT116 nuclear lysates were evaluated 72-hours following knockdown 
for PGC1𝛽, ERR𝛼, and Nrf2 protein expression with HDAC2 serving as a nuclear loading 






























Figure 5.3: Nrf2 regulates the expression of PGC1𝛽 in colon cancer cells. Immunoblot 
analysis was performed on lysates of Nrf2 knockdown cells compared to a non-targeting control 
of HCT116, SW480, and FET cells.  Nuclear lysates were evaluated for PGC1𝛽 and Nrf2 protein 
expression with HDAC2 serving as a nuclear loading control. These data are representative of at 






















knockdown. However, initial analysis following PGC1𝛽 knockdown did not show a decrease in 
Nrf2 protein expression in colon cancer cells. Knocked down of Nrf2, on the other hand, led to a 
decrease in PGC1𝛽 expression (Figure 5.2). ERR𝛼 protein expression was decreased following 
Nrf2 knockdown, which is intuitive given PGC1𝛽 regulates ERR𝛼 expression325. We then 
performed a similar experiment in several CRC cell lines to ensure it was not a cell-specific 
event. Indeed, we observed the decrease of PGC1𝛽 protein levels following Nrf2 knockdown in 
three CRC cell lines (Figure 5.3).   
Since PGC1𝛽 is a vital player in colon cancer cell metabolism, we began more studies 
looking at Nrf2 in colon cancer. To ensure that canonical Nrf2 signaling is present in HCT116 
cells, we knocked down Nrf2, Keap1, the repressor of Nrf2, and NQO1, a downstream target 
enhanced by Nrf2 signaling (Figure 5.4). Following Nrf2 knockdown, we did not see a change in 
Keap1 expression, but we saw complete ablation of NQO1 protein expression. Following 
treatment with the siRNA targeting Keap1, we validated Keap1 knockdown by observing a 
decrease in Keap1 protein expression. Similarly, NQO1 protein expression is significantly 
upregulated following Keap1 depletion. Lastly, validation of NQO1 siRNA was successful as 
NQO1 protein expression was significantly decreased.  
After it was determined that PGC1𝛽 is regulated by Nrf2, we sought to understand if the 
role of Nrf2 was necessary for HCT116 colon cancer cell survival. First, we performed an 
AlamarBlue assay. This assay works by incorporating a redox indicator, resazurin, that fluoresces 
in response to chemical reduction of growth medium following cell growth, converting the small 
molecule to resorufin. AlamarBlue is reduced by the removal of oxygen and its replacement with 
hydrogen from the electron transport chain409. Following Nrf2 siRNA treatment of HCT116 cells, 
the cells were treated with AlamarBlue. After subsequent readings, the cells with Nrf2 












Figure 5.4: Canonical Nrf2 signaling is maintained in HCT116 cells. Immunoblot analysis 
was performed on lysates of Nrf2, Keap1, or NQO1 knockdown cells compared with cells treated 
with a non-targeting control. HCT116 whole cell lysates were evaluated for expression of Keap1, 
a Nrf2 repressor, and NQO1, a downstream Nrf2 target gene, protein expression with 𝛽-actin 
























Figure 5.5: Nrf2 affects cell viability in HCT116 cells. AlamarBlue analysis was performed on 
cells following 72-hours of Nrf2 knockdown and compared to cells treated with a non-targeting 
control. Relative fluorescent intensity of AlamarBlue dye was measured and statistical 
significance was determined by a Student’s t-test. (n=6). These data are representative of at least 












































(Figure 5.5). However, with only one replicate, it is difficult to conclude if these data are 
biologically significant.   
Similarly, a CellTiter-Glo assay was performed to evaluate viability in anchorage 
independent conditions. After plating on poly(HEMA)-coated plates, the CellTiter-Glo solution 
lyses the cells and the luciferin reagent reacts with intracellular ATP and oxygen. This leads to 
active luciferase and a luminescent signal. CellTiter-Glo was added to both control and Nrf2 
knockdown cells. Readings were taken on Day 0 of the experiment and values were reported on 
Day 3. Luminescent signal in Nrf2 knockdown cells was approximately 40% lower than that of 
the control cells (Figure 5.6).   
An evaluation of cell death was performed to understand if Nrf2 was necessary for cell 
survival. HCT116 cells were treated with both Annexin V and PI stain. Both detached and 
attached cells were collected for this analysis. Annexin V staining is a sensitive method for 
detecting early cellular apoptosis. Propidium Iodide (PI) staining is used to detect late apoptotic 
cells. Significant uptake of PI stain corresponds to necrotic cells. This assay was done on both 
control HCT116 cells and Nrf2 knockdown cells. The percentage of early apoptotic cells were 
increased nearly 3.6-fold in Nrf2 knockdown cells (Figure 5.7). The percentage of late apoptotic 
cells was approximately double in the Nrf2 knockdown cells. The percentage of necrotic cells 
increased in the Nrf2 knockdown cells by approximately 1.6-fold. Despite the concern that these 
data are the product of just one sample, the results indicate an increase in cell death following 
Nrf2 knockdown when compared to control HCT116 cells.  
It has been reported that oncogenic proteins increase the transcription of Nrf2176. 
Similarly, aryl hydrocarbon receptor (AhR) and NF-κB have also been shown to regulate 
transcription of Nrf2410,411. However, there have not been studies regarding the promotion of Nrf2 
expression by these proteins in colon cancer. Given that colon cancer is highly K-Ras-driven, we 
sought to understand if Nrf2 was being driven by K-Ras in colon cancer cells. Following 





Figure 5.6: Nrf2 affects cell viability in HCT116 cells under anchorage-independent 
conditions. CellTiter-Glo analysis was performed on Nrf2 knockdown cells and compared to 
cells treated with a non-targeting control. Following growth on Poly(HEMA)-coated plates, cells 
were treated with CellTiter-Glo reagent and relative luminescence was evaluated and statistical 
significance was determined by a Student’s t-test. (n=6). These data are representative of at least 





































Figure 5.7: Nrf2 knockdown increases apoptosis in HCT116 cells. Analysis of cell death was 
performed using Annexin V and PI stain. Upon flow cytometry analysis, the percentage of cells 
with either Annexin V or PI stain with or without Nrf2 knockdown was measured. Early 
apoptotic cells showed high Annexin V stain and low PI stain, late apoptotic cells showed high PI 
stain and high Annexin V stain, and necrotic cells showed high PI stain and low Annexin V stain. 

































Given that there is little oncogenic signaling or oxidative stress in non-transformed 
HCECs cells, we would not expect K-Ras or ROS to be driving Nrf2 expression. In untreated 
HCECs, we see very little Nrf2 protein expression (Figure 5.9). Similarly, we have reported 
previously112, and repeated here, that there is little to no expression of PGC1𝛽 and ERR𝛼	in	these	
cells. Following the transfection of a wild-type Nrf2 construct, we see robust expression of Nrf2 
in HCEC cells. Surprisingly, following the expression of Nrf2, we see expression of both PGC1𝛽 
and ERR𝛼. These data reinforced the hypothesis that Nrf2 drives PGC1𝛽 and ERR𝛼 expression, 
even in cells that do not express the proteins basally.  
 Next, we wanted to investigate the effect of chemotherapeutics on Nrf2 activity in colon 
cancer cells. As previously stated, chemotherapeutics can generate an increase in ROS. We 
treated SW480 colon cancer cells with oxaliplatin, a chemotherapeutic that is typically used to 
treat advanced colorectal cancer in combination with additional agents412. Cells at 0 hour, 5 hours, 
and 24 hours. After Western blotting for Nrf2, we see an increase of Nrf2 protein expression at 5 
hours of treatment compared to 0 hours (Figure 5.10). Subsequently, we see the level of Nrf2 
protein expression decrease at 24 hours of treatment, compared to 5 hours. We would expect a 
similar result with PGC1𝛽 and ERR𝛼 protein expression, given the data correlating PGC1 and 
ERR proteins with therapeutic resistance413. 
 The data connecting PGC1𝛽 and Nrf2 begin to conflict as we examined mitochondrial 
membrane potential. The mitochondrial membrane potential of the inner mitochondrial 
membrane is a readout for the production of ATP, since it is altered significantly by the electron 
transport chain. Cancer cells generally have a higher mitochondrial membrane potential due to 
their increased glycolytic rate. To test mitochondrial membrane potential in HCT116 cells, we 
knocked down PGC1𝛽 and Nrf2 and compared the data with a non-targeting control. We 






Figure 5.8: K-Ras regulates Nrf2 protein expression in colon cancer cells. Immunoblot 
analysis of Nrf2 and pan-Ras protein expression in K-Ras knockdown cells was compared to the 
levels of the proteins in cells treated with a non-targeting control in SW480, T84, and FET cells. 



















TMRE. This molecule penetrates and accumulates inside healthy mitochondria. However, once 
the polarity of the mitochondrial membrane is compromised, TMRE cannot accumulate in the 
mitochondria and is washed away. FCCP is an ionophore that promotes the transport of hydrogen 
ions through the mitochondrial membrane. Thus, TMRE cannot accumulate in the mitochondria 
of FCCP-treated cells, making it an appropriate positive control. In addition to the TMRE stain, 
we normalized the TMRE fluorescence to that of a total mitochondria stain, MitoTracker Green. 
This eliminated the concern for the number or size of mitochondria skewing the data obtained 
with TMRE staining.  
 TMRE staining revealed a decrease of about 40% in median fluorescence in FCCP-
treated cells compared to the control (Figure 5.11A). Similarly, the median fluorescence of 
TMRE stain was decreased approximately 50% in Nrf2 knockdown cells compared to the control. 
Surprisingly, we did not see a change in TMRE staining in the PGC1𝛽 knockdown cells. In order 
to investigate this further, we separated the TMRE staining data from the mitochondria staining 
data. When we did this, we noted a marked increase of over 3-fold in mitochondria staining and a 
matching increase in TMRE staining in PGC1𝛽 knockdown cells (Figure 5.12B). These data 
suggest that PGC1𝛽 knockdown cells have an increase in mitochondria number or size and the 
mitochondria are healthy considering the corresponding TMRE staining, which is not the case 
with Nrf2 knockdown cells.   
 The data also deviates between Nrf2 and PGC1𝛽 knockdown when investigating oxygen 
consumption rate using the Seahorse. As described in the previous chapter, PGC1𝛽 knockdown 
significantly decreases the profile of oxygen consumption rate in CRC cells. However, when Nrf2 
is knocked down, we do not see a decrease in oxygen consumption rate (Figure 5.12).   
 
Conclusions and Discussion 




mitochondrial ROS levels. While there is no previous literature suggesting a relationship between 
Nrf2 and PGC1𝛽, we were surprised to learn that Nrf2 is regulates PGC1𝛽 as opposed to vice 
versa. On the Neh7 domain of Nrf2 there is a binding site for RXR proteins. There is also 
evidence that PGC1 functions as a transcriptional coactivator for RXRs414. This may suggest a 
potential loop in which PGC1𝛽 activates RXRs, which then facilitate RXR binding to Nrf2. 
However, if this theory were correct, it would likely not be a rate limiting mechanism because we 
do not see a decrease of Nrf2 located in the nucleus following PGC1𝛽 knockdown.  
Despite significant effort, we were unable to determine if the regulation of PGC1𝛽 by 
Nrf2 was transcriptional in nature. Other potential regulatory mechanisms that Nrf2 could be 
having on PGC1𝛽 expression include protein stability or posttranslational modifications to 
decrease PGC1𝛽 expression and signaling. However, we did perform RNA sequencing analysis 
in Nrf2 knockdown HCT116 cells compared to the control cells. Although the analysis of the 
RNA sequencing data may not have been properly normalized, the data do not suggest a 
transcriptional regulation of Nrf2 on PGC1𝛽 mRNA expression.  
 We also validated that canonical Nrf2 signaling is at play in HCT116 cells. Nrf2 
knockdown led to a decrease in target protein NQO1. Also, Keap1 knockdown, suggests a 
decrease of repression of Nrf2 signaling and a large increase in NQO1 because of the 
overactivation of Nrf2. However, with Nrf2 knockdown, Keap1 protein expression is stable. In 
this case, there is no Nrf2 binding to Keap1, which leads to the question of whether there is a 
function of Keap1 independent of its Nrf2 repressive function. While there is no literature 
detailing a function for Keap1 independent of its role in repressing Nrf2, there is one study that 
suggests GSK3β can mediate Nrf2 independent of Keap1 in acute kidney injury415 leading to the 
possibility that Keap1 has alternative function and binding partner, such as p53-induced protein 
with a death domain (PIDD) in cancer416. However, it is also possible that Keap1 protein is left 




   
 
 
Figure 5.9: Nrf2 induces PGC1𝛽 and ERR𝛼 protein expression in normal, non-transformed 
human colon epithelial cells. Immunoblot analysis was performed to determine the expression 
of Nrf2, PGC1𝛽, and ERR𝛼	protein	in HCEC cells transfected for 72-hours with Nrf2 
overexpressing construct or vector only (Vo) control. HDAC served as a nuclear loading control. 











Nrf2 binds to the ARE motif of antioxidant genes to transcriptionally activate them and 
enhance the antioxidant response system. Similarly, there are transcriptional cofactors that assist 
in Nrf2’s role of DNA binding and stabilization of Nrf2. These cofactor proteins include small 
Maf proteins386, c-Jun417, and CREB binding proteins418. It is possible that if Nrf2 is expressed to 
enhance tumor growth, then the cofactors expression and activation would likely also play a role 
in enhanced tumor growth as well. Single nucleotide polymorphism of Maf proteins can lead to 
stabilization of Nrf2, thus causing tumor suppression419,420. Similarly, mutations and knockdown 
of Maf proteins can lead to increase tumor progression421,422. C-Jun, another cofactor of Nrf2, is 
also overexpressed in breast cancer and non-small cell lung cancer, suggesting it is enhancing 
tumor growth423,424. Lastly, inhibition of CREB binding proteins has been successful in leukemia 
therapy425. Although these cofactors can assist other transcription factors, it is plausible that they 
enhance Nrf2 signaling in progressing tumor formation. Future work would be necessary to 
understand if these cofactors are necessary for colon cancer progression and, if so, if inhibition by 
small molecules would decrease Nrf2 signaling. 
 Similar to the cofactors that assist Nrf2 signaling, transcriptional regulators also play an 
important role in mitigation of ROS and oxidative stress. Here, we demonstrated that the 
oncogene K-Ras plays a vital role in Nrf2 protein expression, similar to that of other cancer 
models. However, in the Western blot displaying a decrease in Nrf2 protein expression following 
K-Ras knockdown (Figure 4.8), there is a differential decrease of Nrf2 in the three cell lines. This 
may be due to the different mutations in the three cell lines. For example, T84 cells have mutant 
K-Ras and mutant p53 while FET cells are only mutant in p53, which may explain why there is a 
smaller decrease in Nrf2 protein expression after K-Ras knockdown in FET cells. Similarly, 
SW480 cells are mutant in Fos, which can be a cofactor of Nrf2, which makes K-Ras only a 
partial activator of Nrf2, resulting in a slightly smaller decrease of Nrf2 protein expression 
following K-Ras knockdown. However, the fact that the oncogenic driver, K-Ras, at least in part, 







Figure 5.10: Nrf2 expression increases five hours following treatment with a 
chemotherapeutic in SW480 cells. Immunoblotting was used to determine Nrf2 protein 
expression in SW480 cells treated with 100μM of Oxaliplatin after 0, 5, or 24 hours. HDAC2 
















signaling. Although there was only a moderate decrease in cell viability as shown in the 
AlamarBlue and CellTiter-Glo assay, there was a much more significant increase in the 
percentage of cells undergoing different levels of apoptosis. One explanation for this is that we 
collect both attached and detached cells for the apoptotic measurements and the viability 
measurements only assess attached cells. These experiments suggest that there is more death 
leading to detached cells. This may suggest that Nrf2 is contributing less to metabolic 
reprogramming of the cancer cells and much more to the health of the mitochondria and thus the 
health of the cell. This conclusion is confirmed by the Seahorse data following Nrf2 knockdown 
showing no decrease in oxygen consumption rate. 
 While K-Ras is one oncogenic gene that has been known to drive Nrf2 transcription, 
there are other oncogenes such as B-RAF and MYC176. Aside from oncogenic drivers of Nrf2, 
there is some evidence that AhR, another transcriptional activator of Nrf2, is enhanced in colon 
cancer as well as breast, prostate, gastric, and non-small cell lung tumors426-432. This literature 
suggests that AhR may be enhancing Nrf2 transcription to enhance tumor growth. In addition to 
AhR, other transcriptional regulators such as NF-κB, Notch, and PI3K/AKT have also been 
shown to augment Nrf2 transcription, in some cases in tumor cells141,411,433. Similarly, loss of 
Keap1, and thus increasing Nrf2 signaling, can accelerate mutant K-Ras driven lung cancer434,435 
but could have a similar effect in colon cancer. Overall, though K-Ras drives tumorigenesis in 
colon cancer, and is a likely transcriptional regulator of Nrf2, there are other possibilities of 
regulation. Future work should include mRNA analysis of Nrf2 following K-Ras knockdown to 
ensure that the oncogenic gene is in fact affecting the transcription of Nrf2. 
 Although we hypothesize that Nrf2 is regulated transcriptionally in colon cancer, it is 
possible that regulation of Nrf2 includes protein stability, localization, or post-transcriptional 
modifications. Alternative splicing of Nrf2, specifically transcripts missing exons 2 and 3, which 
are necessary to interact with Keap1 have been observed in certain cancers which can alter the 







Figure 5.11: Evaluation of mitochondrial membrane potential in HCT116 cells. (A) 
Mitochondrial membrane potential in PGC1𝛽 or Nrf2 depleted colon cancer cells was evaluated 
using TMRE stain. FCCP treated cells serve as a positive control. Median fluorescence of TMRE 
staining is normalized to total mitochondria staining and to the control cells. (n=3). These data are 
representative of at least two independent experiments. ** = p-value < 0.01. (B) Median 
fluorescence of TMRE or Mitotracker Green stain was measured in PGC1𝛽 or Nrf2 depleted 
HCT116 colon cancer cells. FCCP treated cells serve as a positive control. Median fluorescence 
of TMRE staining is a measurement of mitochondria membrane potential and median 
fluorescence of MitoTracker green is a measurement of overall mitochondria. (n=3). These data 
are representative of at least two independent experiments. 
cells. The obvious regulatory mechanism of Nrf2 protein is through its interaction with Keap1, as 








































Nrf2 is sequestered in the cytoplasm and degraded. This interaction can be regulated by PKC, 
namely through disruption of the Neh2 domain on Nrf2 decreasing interaction with Keap1, 
promoting Nrf2 activation437,438. However, Keap1 is not the only negative regulator of Nrf2. Hrd1 
can also repress Nrf2 signaling by destabilizing the protein439. Lastly, Nrf2 is only active through 
nuclear localization so regulation through subcellular localization is also a substantial regulatory 
mechanism. Progerin, a truncated version of the lamin A protein, has been shown to trap Nrf2 at 
the nuclear periphery and impair its activity440. There is also evidence of promotion of 
tumorigenesis progression by progerins in prostate and lung cancer441,442.   
 The data presented here also suggests that Nrf2 overexpression in non-transformed 
HCECs is causes an increase in PGC1𝛽 and ERR𝛼 expression that HCECs otherwise lowly 
express. While we have previously reported that PGC1𝛽 and ERR𝛼 are lowly, if at all, expressed 
in HCECs112, it is curious as to why there is very little to no expression of Nrf2 in the untreated 
HCECs. Since normal intestinal mucosa grows at much lower oxygen concentration than other 
tissues443, we grow the HCECs in a hypoxia chamber containing 2% oxygen. While this could 
skew the level of Nrf2 signaling in the HCECs, it is also likely that normal cells have less 
oxidative stress due to a more appropriate balance of ROS from a more controlled electron 
transport chain. Normal cells are also more likely to undergo apoptosis following high ROS 
levels as opposed to activating an antioxidant response to evade cell death, a common response in 
cancer cells.  
 Although Nrf2 has been shown to regulate PGC1𝛽 and ERR𝛼, the data diverges after 
testing the mitochondrial membrane potential of cells with PGC1𝛽 or Nrf2 knockdown. As 
expected, Nrf2 knockdown leads to a significant dysfunction of mitochondrial membrane 
potential. This is likely because of the imbalance of ROS from a lack of antioxidant genes. 
However, following PGC1𝛽 knockdown, we do not see a change in mitochondrial membrane 





Figure 5.12 Nrf2 expression does not affect the maintenance of oxidative phosphorylation in 
colon cancer cells: HCT116 cells were treated with either Nrf2-targeted (green) or non-targeted 
(red) siRNA. Oxygen consumption rate (OCR, pmol oxygen per minute) was measured over time. 
Oligomycin, FCCP, and rotenone were added at the indicated timepoints. These data are 













extrapolated, we see a large increase in mitochondria staining that is matched with that of TMRE 
staining. These data are surprising and possibly suggest that PGC1𝛽 knockdown enhances either 
overall number or size of mitochondria and the mitochondria that are present are healthy, despite 
the ROS increase. This differential phenotype with Nrf2 knockdown compared to PGC1𝛽 
knockdown suggests that Nrf2 may be functioning independent of its role in regulating PGC1𝛽. 
However, the data still leads to the question of why a depletion of PGC1𝛽 leads to both an 
increase in ROS and an increase in mitochondrial staining, while the mitochondria remain 
healthy. Although there is no direct literature detailing why a decrease in mitochondrial 
biogenesis gene, PGC1𝛽, would cause an increase in mitochondria density, one study speculates 
that an increase in mitochondria may be related to oxygen supply and movement of high energy 
phosphate compounds out of the mitochondria444. Similarly, some polar animals have a high 
density of mitochondria to survive colder climates445 suggesting that the increase in mitochondria 
could be a thermogenic response, which has been shown to be modulated by PGC1𝛽201. 
Looking into the metabolic profile of Nrf2 knockdown cells, it is clear that they do not 
follow the same trend as PGC1𝛽 knockdown cells. After knockdown of Nrf2, we do not see a 
decrease in oxygen consumption rate compared to the control. This is in contrast to the marked 
decrease we see following PGC1𝛽 knockdown. We were interested in understanding how PGC1𝛽 
is altering the metabolism of colon cancer cells and since Nrf2 does not seem to be leading to this 
effect, we began investigating downstream targets of PGC1𝛽 that could be leading to the strong 





















Chapter 6: PGC1𝛽 and ERR𝛼 Promote Colon Cancer 













Phosphoenolpyruvate carboxykinase (PEPCK) is responsible for converting oxaloacetate 
into phosphoenolpyruvate (PEP) and carbon dioxide to feed into the gluconeogenesis pathway446-
448. There are two isoforms of PEPCK, a cytosolic form (PCK) and a mitochondrial form (PCK2) 
that share over 60% homology in structure (Uniprot). PCK/PCK2 catalyzes the irreversible 
decarboxylation and phosphorylation of oxaloacetate which is the rate-limiting step in 
gluconeogenesis449-452. PCK/PCK2 regulate the level of metabolic intermediates in the TCA 
cycle. In low glucose levels, PCK/PCK2 can convert oxaloacetate to PEP and can alter its role to 
more anaplerotic reactions in high glucose conditions449. Due to these functions, PCK1/2 
facilitates the metabolism of non-carbohydrate sources such as glutamine, lactate, and TCA cycle 
intermediates under nutrient starvation453,454.  
 
PEPCK Structure 
Although the PCK1 and PCK2 genes are located on chromosome 20 and 14, respectively, 
the structure of these isoforms is well-conserved. The regions that are not conserved on the 
structure consist of 10 exons, though only 9 are coding regions on PCK1, while PCK2 contains 
all 10 coding exons455-458 but both isoforms have residues that are ideal for post-translational 
modifications.  PCK1 transcription is enhanced by PKA, ATF2, and Jun while ATF3 represses 
activation459-461. Although there is less literature available, ATF4 has been shown to induce PCK2 
transcriptionally448. Several other potential transcription factor binding regions have been 
identified bioinformatically, though there is no biological validation 462.  
 
PEPCK Regulation 
The transcriptional regulation of PCK1 has been characterized extensively while the 




have been reported in certain ethnic populations467,468 and there is also evidence of sequence 
variations at 1097 and 967 bp which led to functional consequences pertaining to the PPARγ 
mediated PCK1 regulation469,470. Similarly, there are only Adenine-Uridine Rich Elements 
encoded in the PCK1 gene, not present in the PCK2 isoform, suggesting a possible mechanism 
for PCK1 regulation distinct from PCK2 462. Epigenetic methylation of DNA is thought to 
suppress PCK1 expression471 while acetylation of PCK1 protein increases its stability472,473. 
Similarly, miRNAs influence PCK1 levels in response to metabolic signals including miR-29a474. 
There are nearly a dozen miRNAs predicted bioinformatically to bind to PCK2 though not 
validated in any biological system. In contrast, CpG islands in PCK2 overlap with the first exon 
while they do not in PCK1462,475. PCK1 expression has been shown to be primarily dependent on 
glucagon in rats during development476, while in chicks PCK1 was expressed during the early 
embryonic period while PCK2 expression was more prominent postnatally477.  
 
PEPCK in cancer 
Although PCK2 knockout mice are viable and PCK1 knockout mice are not478, mice are 
not a great model for studying PCK proteins because the ratio between PCK1 and PCK2 is 
approximately 9:1. Thus, there is little in vivo exploration of the role of PCK2, although recent 
research suggests its involvement in cancer479,480. As has been established, increased glycolysis 
and OXPHOS is required to enhance energy in tumor cells481. In order to enhance activation of 
the enzymes responsible for glucose metabolism, glutamine or lactate can enter the TCA cycle to 
compensate for glycolytic intermediates required for ribose and serine synthesis supporting cell 
proliferation448,453. In colon cancer cells, p53 was shown to downregulate PCK1482, but increase 
PCK2 levels in HCC483. Similarly, PCK1 promotes glutamine usage and induces metabolism 
through mTORC1 activation, but not mTORC2, in colon cancer148. Lung cancer cells showed 
only expression of PCK2, not PCK1 and PCK2 was induced by low glucose concentrations as 




the synthesis of metabolic intermediates for tumor growth in low glucose conditions453. Another 
study in lung cancer shows that PCK2 reprograms the cells to generate PEP from glutamine in 
order to conserve glucose pools479. In breast cancer, ATF4 was shown to bind to the promoter of 
PCK2, upregulating the protein level of PCK2 and enhancing pro-survival mechanisms under 
amino acid depletion448. In prostate cancer, PCK2 knockdown resulted in a decrease in tumor 
initiating cells by lowering acetyl-CoA levels through reduced TCA cycle function484. Decreased 
PCK2 expression reduced carbon flow from fumarate in the TCA cycle causing dysfunction of 
oxidative phosphorylation in tumor-repopulating cells of melanoma485. Overall, it is clear that 
PCK2 plays a vital role in cancer cell metabolism, specifically by directing carbon sources to 
enhance the TCA cycle.  
Aside from cancer, PCK proteins plays a role in other diseases, as well as aging. In 
hepatitis, high PCK2 expression causes an onset of metabolic disorders486. Similarly, the CMV 
virus increases the expression of both PCK isoforms to generate energy through conversion of 
oxaloacetate to pyruvate by utilizing glutamine as a substrate from the TCA cycle487. PCK1 was 
also shown to have a role in aging, as there is an increase in glucose in older rats compared to 
younger rats488, yet there is no data on changes in PCK2 with increased age.  
Due to our data citing PCK2 downregulating following PGC1𝛽 or ERR𝛼 knockdown and 
given the recent investigation of PCK2 in diseases, including cancer, we sought to understand the 
regulation and functional role of PCK2 in colon cancer.  
 
Results 
Given the prominent effect of PGC1𝛽 and ERR𝛼 on metabolism in colon cancer cells, we 
sought to define specific downstream effectors of both PGC1𝛽 and ERR𝛼. HCT116 cells were 
transfected with individual siRNAs targeting either PGC1𝛽 or ERR𝛼 in comparison with non-






Figure 6.1: PGC1𝛽 and ERR𝛼 regulate PCK2 mRNA levels. PCK2 mRNA levels of either 
(A) HCT116 or (B) T84 cells were measured using RT-qPCR following knockdown with 
individual siRNA oligos of either PGC1𝛽 or ERR𝛼 and a non-targeting control for 72-hours. 
RNA was isolated from the cells and RT-qPCR was performed to evaluate a change in Ct values. 
Fold change was assessed as described in the methods section. * = p-value < 0.05, ** = p-value < 
0.01, *** = p-value < 0.001. These data are representative of at least two independent 













oligos for each target. The total mRNA was isolated from each sample and RNA-sequencing 
were performed. Following the deSeq2 analysis of the data, the genes were ranked in descending 
order by p-value (Table 1). As seen previously, PGC1𝛽 and ERR𝛼 enhance metabolic processes 
in many model systems, so it was not surprising that many metabolic genes were downregulated 
with PGC1𝛽 and ERR𝛼 knockdown. We were particularly interested in the statistically 
significant downregulated genes of both PGC1𝛽 and ERR𝛼 compared to the control. These genes 
included MTHFD2, PHGDH, and PSAT1 that cluster with the serine synthesis pathway. 
Similarly, ASNS, GPT2, OGDHL, and ASCT1 (SLC1A4) clustered with Glutaminolysis and the 
TCA cycle (Table 2 in Chapter 4).  
The most significantly downregulated gene by both PGC1𝛽 and ERR𝛼 knockdown 
compared to the control was Phosphoenolpyruvate Carboxykinase (PEPCK-M or PCK2). We 
focused on PCK2 because it is a prominent metabolic regulatory gene and the main enzyme that 
exists at the junction between glycolysis and the TCA cycle. The two isozymes of PEPCK (PCK1 
and PCK2) are responsible for decarboxylating and phosphorylating oxaloacetate to convert it 
into PEP, which is the first committed step in gluconeogenesis489. As glucose levels decrease in 
under perfused tumor areas, gluconeogenesis generates glucose to address low glucose conditions 
in non-small cell lung cancer453. In breast cancer, PCK2 knockdown reduced cancer cell growth 
and increased cell death under nutrient deprivation448. Very little is known about the role PCK2 
plays in colon cancer metabolism. Surprisingly, our data show that only the PCK2 isozyme is 
significantly downregulated while PEPCK-C or PCK1 is unchanged by PGC1𝛽 or ERR𝛼 
knockdown. Relative to PCK1, there is little literature on PCK2 especially in regard to cancer 
research.  
To validate the RNA sequencing results, we repeated the experiment in a more targeted 
manner. In addition to knocking down PGC1𝛽 and ERR𝛼 in HCT116 cells, we expanded the  






Figure 6.2: PGC1𝛽 and ERR𝛼 regulate PCK2 protein expression. HCT116 and T84 cells 
were transfected with a pool of validated (A) PGC1𝛽 or (B) ERR𝛼 siRNAs and Western blot 
analysis was performed to assess PCK2 protein expression. Validation of PGC1𝛽 or ERR𝛼 
knockdown were confirmed in respective Western blots. 𝛽-actin serves as a loading control. 
These data are representative of at least two independent experiments. Figure 6.2 was 




knocking down the target protein with both oligo sets used in the original RNA sequencing 
experiment, we performed qPCR targeting the PCK2 mRNA (Figure 6.1). The knockdown of 
PGC1𝛽	with siRNA #1 resulted in a 333- and 63-fold decrease of PCK2 mRNA in the HCT116 
and T84 cells, respectively. The knockdown of PGC1𝛽 with siRNA #2 resulted in a 11- and 33-
fold decrease of PCK2 mRNA in the HCT116 and T84 cells, respectively. The knockdown of 
ERR𝛼 with siRNA #1 resulted in a 3- and 5-fold decrease of PCK2 mRNA in the HCT116 and 
T84 cells, respectively. Lastly, the knockdown of ERR𝛼 with siRNA #2 resulted in a 5000- and 
6-fold decrease of PCK2 mRNA in the HCT116 and T84 cells, respectively. The discrepancy in 
the magnitude difference of PCK2 mRNA between target depletion could be explained by the 
transfection efficiency of the two cell lines. HCT116 cells have a higher transfection efficiency 
than T84 cells. We typically observe a more potent knockdown with ERR𝛼 siRNA #2 than that of 
#1, though the reason for this has not been elucidated. The residual expression of the target 
protein following transfection in the T84 cells may explain the lesser degree of mRNA fold 
change, though still statistically significant. These data also correlate with the transcript values of 
PCK2 following the target knockdown compared to the control from the RNA sequencing 
experiment. 
We also confirmed that PCK2 protein expression is decreased with both PGC1𝛽 and 
ERR𝛼 knockdown. Complementary to the mRNA, PCK2 protein is shown to decrease by 
Western blot. A pool of both oligos of PGC1𝛽 or ERR𝛼 decreased PCK2 protein expression 
significantly compared to the control (Figure 6.2).  
We sought to understand the role of PCK2 in CRC cell viability. In the HCT116 and T84 
cells, cell viability was evaluated using CellTiter-Glo and AlamarBlue. CellTiter-Glo uses 
luminescence that correspond to ATP levels. The level of ATP has been shown to correspond to 
the viability of the cells. This experiment was performed using poly-(HEMA) coated plates. With 






Figure 6.3: PCK2 enhances colon cancer cell viability and survival but is dispensable for 
normal cells. (A) AlamarBlue fluorescence was measured in HCT116, T84 cells, or HCECs 
treated with either control (black bars, n = 6) or PCK2 (gray bars, n = 6) siRNA for 72-hours. 
Cells were plated on white-bottom, white-sided 96-well plates after the 72-hour transfection, a 
1:10 ratio of AlamarBlue reagent to original volume plated was added. Cells were incubated at 
37∘C for 1 hour before measuring the fluorescence. Control values were normalized to 1 and 
PCK2 knockdown values were compared to control using a Student’s t-test. These data are 
representative of at least two independent experiments.  (B) HCT116, T84 cells, or HCECs were 
transfected with either control or PCK2 siRNA. Cells were lysed and samples were resolved on 




using corresponding antibodies and LI-COR secondary antibodies. Imaging of the membranes 
was performed on a LI-COR Odyssey. PCK2 probing serves as a verification of knockdown. 𝛽-
actin is used as a loading control. These data are representative of at least two independent 
experiments. (C) CellTiter-Glo luminescence was measured in HCT116 or T84 cells treated with 
either control (black bars, n = 6) or PCK2 (gray bars, n = 6) siRNA for 72-hours. Cells were 
plated on poly-(HEMA) coated 96-well plates 24-hours after beginning the knockdown. A zero-
hour reading was taken at the time of plating. 48-hours after plating, the cells were evaluated for 
viability using 1:1 ratio CellTiter-Glo reagent to the volume of medium originally plated. 
Luminescence was measured on a luminometer following gentle agitation. All measurements 
were normalized to the zero-hour reading. Subsequently, control values were normalized to 1 and 
PCK2 knockdown values were compared to control using a Student’s t-test. These data are 












Figure 6.4: PCK2 depletion trends toward an increase in colon cancer cell apoptosis but not 
for normal cells. Apoptotic cells were measured in HCT116, T84, and HCEC cells with or 
without PCK2 knockdown. Apoptosis was evaluated using Annexin V and PI staining. Relative 































Figure 6.5: PCK2 alters the transforming capacity of colon cancer cells. Transforming 
capacity was evaluated by growing SW620, HCT116, and HT-29 cells with and without stable 
PCK2 knockdown on NuSieve agar to model anchorage-independent conditions. Representative 
images were taken (A) and colonies were counted (B). A Student’s t-test was performed to assess 
statistical significance. (n=6) **** = p-value < 0.0001. These data are a summary of one 















Figure 6.6: PCK2 depletion in HCECs does not affect cell growth. HCECs were transfected 
with PCK2 siRNA or a non-targeting control. After plating cells evenly, cells were counted over 
subsequent days (day 2, day 4, day 6) and the cell count was plotted (top). Validation that target 
knockdown was maintained at day six was done by PCK2 immunoblotting and PARP expression 
was assessed to ensure apoptosis was not significantly changed over time (bottom). These data 
are representative of at least two independent experiments. 
 

























conditions. Anchorage-independent growth is a hallmark of cancer cells, so we predicted the 
control cancer cells would grow efficiently under these constraints. After PCK2 siRNA 
transfection, the cells were plated on the poly-(HEMA) coated plates. A zero-hour reading was 
taken by treating the cells with CellTiter-Glo shortly after plating. 48-hours following the 
transfection, the cells were treated with CellTiter-Glo and the luminescence was read. The 
luminescence values were normalized to the zero-hour reading. Then, the PCK2 knockdown was 
normalized to the control cells. In the HCT116 cells, PCK2 deficiency decreased the cell viability 
by 38% (Figure 6.3C).  In the T84 cells, PCK2 deficiency decreased the cell viability by 35%.  
We repeated the experiment above with AlamarBlue treatment as a more general metabolic assay. 
In this experiment, a fluorescence value is recorded as the cells metabolize the small molecule, 
resazurin, to resorufin, a strongly fluorescent molecule. A decrease in fluorescence signal 
correlates with a decrease in overall metabolism or viability of the cells. In the HCT116 cells, 
PCK2 deficiency decreased the cell viability by 76% as indicated by the AlamarBlue assay 
(Figure 6.3A). In the T84 cells, PCK2 deficiency decreased the cell viability by 37% in this assay. 
As an additional parameter to determine the necessity of PCK2 expression for CRC cell 
viability, we evaluated the level of apoptotic marker, cleaved-PARP, following PCK2 depletion. 
Enzymes such as caspases cleave the PARP protein which indicates activation of the cell death 
pathway, apoptosis. HCT116 cells transfected with PCK2 siRNA showed substantial decrease of 
PCK2 protein levels with significantly increased levels of cleaved PARP (Figure 6.3B). 
Similarly, T84 cells transfected with PCK2 siRNA showed substantial decrease of PCK2 protein 
levels with significantly increased levels of cleaved PARP. Another measure of apoptosis was 
evaluated in HCT116 and T84 cells used Annexin V and PI staining. The trend suggests that 
following PCK2 knockdown, HCT116 and T84 cells have an increased number of apoptotic cells 
compared to the control (Figure 6.4) 
Cells were evaluated for their transforming capacity following PCK2 knockdown. In this 







Figure 6.7: PCK2 promotes oxidative phosphorylation and glycolysis in colon cancer cells 
but not in normal cells. (A) Baseline OCR was measured by averaging the first five 
measurements of three replicates for either HCT116, T84, or HCEC cells. Control (black bars, n 
= 15) values are normalized to 1 and PCK2 knockdown (gray bars n = 15) values are compared to 
control using a Student’s t-test. (B) Maximal Respiratory Response was calculated by average the 
difference between the OCR values following the addition of FCCP and the OCR values 
following the addition of Rotenone. Control (black bars, n = 9) values are normalized to 1 and 
PCK2 knockdown (gray bars, n = 9) values are compared to control using a Student’s t-test. (C) 
Glycolysis was measured by averaging the difference between ECAR values following the 
addition of glucose and the ECAR values following the addition of 2-DG. Controls (black bars, n 




control using Student’s t-test. (D) Glycolytic capacity was measured by averaging the difference 
between ECAR values following the addition of oligomycin and the ECAR values following the 
addition of 2-DG. Controls (black bars, n = 9) were normalized to 1 and PGC1𝛽 knockdown 
samples (gray bars, n = 9) were compared to control using Student’s t-test. These data are 
representative of at least two independent experiments.  * = p-value < 0.05, *** = p-value < 
























course of two weeks. Knockdown of PCK2 in HCT116, HT-29, and SW620 cells using two 
separate short-hairpin oligos markedly decreased colony formation relative to control cells 
expressing non-targeting shRNA (Figure 6.5). 
Evaluation of the role of PCK2 in normal colon was done by transfecting immortalized, 
but non-transformed HCECs with siRNA targeting PCK2. Following the transfection, the cells 
were evaluated for viability and the apoptotic marker, cleaved PARP. The HCECs were evaluated 
for cell viability using AlamarBlue. Since anchorage-independent conditions are not a 
characteristic of normal colon epithelial cells, the previously described poly-(HEMA) and 
CellTiter-Glo analysis was not possible with the HCEC cells. Following PCK2 knockdown in 
these cells, the AlamarBlue fluorescence remained unchanged compared to control cells (Figure 
6.3A). Furthermore, HCECs with PCK2 knockdown did not show enhanced cleaved PARP 
compared to the control (Figure 6.3B). Next, HCECs were evaluated using Annexin V and PI 
staining, with no change in the relative fluorescence observed in PCK2 knockdown versus control 
cells (Figure 6.4). A growth curve was completed to understand if cells with PCK2 knockdown 
have a differential growth rate compared to control HCEC cells. After transient knockdown, cells 
were evenly plated and counted over a 6-day period. An accompanying Western blot was 
completed on day 6 to ensure PCK2 knockdown was maintained. This analysis showed that 
control HCEC cells and HCECs with PCK2 knockdown show a near identical growth curve 
(Figure 6.6), suggesting PCK2 does not affect survival or viability of normal cells.  
To determine the metabolic effects that PCK2 depletion has in colon cancer cells, 
HCT116 and T84, we analyzed the metabolic flux of PCK2 depleted colon cancer cells via the 
XFe96 Seahorse, similar to Figure 4.1. We used oxygen consumption rate and extracellular 
acidification rate as readouts for oxidative phosphorylation and glycolysis, respectively. Four 
parameters were calculated in HCT116 and T84 cells treated with PCK2 siRNA, as previously 





Figure 6.8: Measurement of mitochondrial membrane potential in PCK2 depleted colon 
cancer cells using TMRE. HCT116 cells with PCK2 knockdown or non-targeting control were 
evaluated for mitochondrial membrane potential using TMRE stain. FCCP treated cells serve as a 
positive control. Median fluorescence of TMRE staining is normalized to 1 in the control cells. 












to the control (Figure 6.7A). In T84 cells without PCK2, baseline OCR was decreased nearly 3-
fold compared to the control. Maximum respiratory response was decreased by 8-fold in both the 
HCT116 and T84 cells depleted of PCK2 expression (Figure 6.7B). PCK2 depletion led to a 
decrease in glycolysis levels of 11-fold and 1.6-fold in the HCT116 and T84 cells, respectively 
(Figure 6.7C). PCK2 depletion decreased glycolytic capacity by 12-fold and 2-fold in the 
HCT116 and T84 cells, respectively (Figure 6.7D). Due to the large metabolic defects seen with 
PCK2 knockdown, we investigated the mitochondrial membrane potential to determine if the 
mitochondria were relatively healthy. Similar to what we observed with PGC1𝛽 knockdown, 
PCK2 knockdown does not have a detrimental effect on mitochondrial membrane potential, 
suggesting that PGC1𝛽 and PCK2 are affecting the mitochondria in a similar manner (Figure 
6.8). In contrast, HCECs depleted of PCK2 expression did not exhibit any change in baseline 
oxygen consumption rate (Figure 6.7A) or glycolysis (Figure 6.7C) when evaluated similarly by 
the XFe96 Seahorse. A minor decrease in maximum respiratory rate and glycolytic capacity in 
HCECs without PCK2 expression was approximately 1.4-fold for both measurements (Figure 
6.7B & D). 
Under glucose deficient conditions 490,491, the cancer cells compensate by utilizing lactate 
as a substrate 492,493. Lactate can be converted to pyruvate and acetyl Coenzyme A (Acetyl CoA) 
for use in the TCA Cycle. The TCA cycle ultimately generates precursors that feed into the 
electron transport chain to produce ATP via oxidative phosphorylation 494. The TCA cycle also 
generates other precursors for gluconeogenesis, the process that creates glucose from other 
carbon sources 495,496. Glutamine, another main carbon source for metabolic processes, can also 
play a regulatory role in gluconeogenesis 497,498. Together, these substrates and processes can be 
altered to manipulate metabolism and allow cancer cells to grow and proliferate uncontrollably. 
We sought to understand if one of these carbon sources could negate the effects seen by PCK2 
depletion on oxidative phosphorylation. To do this, we plated HCT116 cells with or without 




was measured by a readout of baseline oxygen consumption rate (OCR). Since extracellular 
acidification rate (ECAR) is largely measured by lactate production, and as stated above, lactate 
production can be skewed, ECAR was not measured in this experiment. Control and PCK2 
knockdown cells were treated with increasing doses of either glutamine or glucose in the 
previously defined Seahorse medium. After an hour incubation, the cells underwent 
measurements of baseline OCR. Increasing concentration of glutamine did not change the 
dramatic decrease in baseline OCR that is seen with PCK2 knockdown compared to the control 
(Figure 6.10). However, at just 50µM of glucose added, an increase in baseline OCR was seen to 
match that of the control. Increasing concentrations of glucose to 200µM, increased the baseline 
OCR of PCK2 depleted cells 2-fold compared to the control. This increased level of baseline 
OCR is sustained through the increase of glucose concentrations.  
PCK2 is responsible for converting mitochondrially-derived oxaloacetate into 
phosphoenolpyruvate. In the TCA-cycle, oxaloacetate is generated from malate by the enzyme 
malate dehydrogenase. To understand the role of PCK2 in the TCA cycle, we knocked down 
PCK2 in HCT116 cells and analyzed the metabolites in the control cells and PCK2 depleted cells. 
From this analysis, we learned that malate, glucose, succinate, and pyruvate were significantly 
depleted from the conditioned medium corresponding to the PCK2 depleted cells (data not 
shown). This suggests that the PCK2 knockdown cells were lacking these metabolites causing an 
uptake from the medium leaving the conditioned medium significantly depleted. It was also 
expected that there would be a buildup of intracellular oxaloacetate as PCK2 would not be 
available to convert it. Indeed, we saw approximately a 6-fold increase of oxaloacetate in the 
PCK2 knockdown cells compared to the control (Figure 6.9).  
The large buildup of oxaloacetate was significant, which led us to analyze the biological 
kinetics of the reaction. One reaction of the TCA cycle that is responsible for converting malate 





Figure 6.9: PCK2 depletion causes marked dysfunction of TCA cycle intermediates through 
a build-up of oxaloacetate. Average metabolite abundance values were measured for 
intracellular oxaloacetate and phosphoenolpyruvate levels in the control (black bars) and PCK2 
knockdown (gray bars) cells. Control samples were normalized to one and PCK2 knockdown 
samples were compared to the control using a Student’s t-test. (n=5). These data are a summary 










malate dehydrogenase (KMDH) and the reaction quotient (Q) derived from the values of the 
metabolomics analysis; the direction of the reaction was determined. The ratio of KMDH to Q in 
the PCK2 knockdown cells was over 12-fold below that of the control (Figure 6.11). This 
indicates that the reaction was being driven more significantly backwards than the control.  
With the understanding that the reaction of malate being converted into oxaloacetate was 
reversed, other metabolites were examined. Upstream of the reversed reaction is citrate and 
isocitrate, the pool of which was decreased 4.5-fold in PCK2 knockdown cells (Figure 6.9). In 
contrast, downstream of the reversed reaction are fumarate and succinate. These metabolites were 
increased by over 2-fold.  
 
Conclusions and Discussion 
These results demonstrate that while PGC1𝛽 plays a significant role in the overall 
metabolic functions of colon cancer cells, this role is, in part, fulfilled by PCK2, a vital kinase 
that functions at the junction of the TCA cycle and glycolysis. We show that depletion of PCK2 
leads to a significant reduction in metabolic processes, similar to that of PGC1𝛽 depletion. 
However, it is clear there are multiple metabolic effectors of PGC1𝛽 that would need to be 
evaluated to understand the full mechanism that PGC1𝛽 plays in cancer metabolism. The driver 
of PCK2 activity and expression also appears to be context dependent. Although this study shows 
that PCK2 is enhanced by PGC1𝛽 and ERR𝛼, other studies have shown ATF4 as a potential 
regulator 447. We are confident that PCK2 is driven by the transcription factor ERR𝛼 given that 
there are many bioinformatically identified Estrogen Related Response Element (ERRE) motifs 
near and within the PCK2 gene. We have determined this by overlaying the PCK2 exons with 
ERRE motifs identified through two separate databases. Since PGC1𝛽 and ERR𝛼 are not 
expressed in HCECs, there must be a separate regulatory mechanism taking place in the normal 





Figure 6.10: PCK2 utilizes glutamine to stabilize baseline OCR in HCT116 cells. Baseline 
OCR was measured by averaging five measurements for each of the three biological replicates of 
either PCK2 knockdown or control cells. The cells were treated with medium containing 
increasing glutamine (top) or glucose (bottom) concentrations for one hour prior to the metabolic 
reading. (n=3). These data are representative of at least two independent experiments. ** = p-





enhancer of PCK2. Since PCK2 is dispensable in HCECs, it is plausible that the mechanism of 
PCK2 regulation in normal cells can be easily compensated for. We do not expect that the 
compensatory mechanism would involve PCK1 since the hormones and nutrients that regulate 
PCK1 do not transcriptionally regulate the coding of PCK2447.   
PCK2 expression is more abundant in normal colon cells (HCECs) than in colon cancer 
cells, which was the rationale one study did not focus on PCK2 in colon cancer 148. Preliminary 
data (not shown) suggest that although PCK2 is much less expressed in the cancer cells, but the 
role PCK2 plays must be more vital because of the detrimental effects seen when PCK2 is 
depleted. One explanation for this could be that cancer cells require large amounts of glucose to 
increase metabolic processes that enhance their excessive proliferation. PCK2 depletion 
effectively halts the gluconeogenesis pathway and restricts the amount of nutrients available for 
the cancer cell. This would also provide rationale for the data that increased glucose 
concentrations rescues the decrease in baseline OCR seen with PCK2 depletion. Increasing 
glutamine levels has shown to increase cell growth and proliferation as well as supplying carbon 
and nitrogen for generation of biosynthetic precursors499,500. However, it was not enough to 
overcome the large detriment of baseline OCR seen with PCK2 depletion. This could be 
explained by the fact that the TCA cycle is not functioning correctly. Since glutamine would feed 
the intermediates of the TCA cycle, but eventually stall out due to the lack of PCK2 expression 
and subsequent buildup of oxaloacetate, there is no amount of glutamine that could overcome 
this. It has been shown that PCK2 activity increases the TCA cycle by sourcing PEP toward 
pyruvate formation to feed acetyl-CoA 447. However, bypassing the TCA cycle and 
gluconeogenesis by adding significant amounts of glucose was sufficient to enhance oxidative 
phosphorylation regardless of PCK2 expression. These data are in agreement with previous 
reports that PCK2 depletion decreased breast cancer cell growth when glutamine was deprived 
448.  PCK2 depleted colon cancer cells significantly decreased the metabolic parameters that we 







Figure 6.11: PCK2 depletion causes a dysfunction in kinetics of a vital TCA cycle reaction. 
(Top) The ratio of the equilibrium constant and the reaction quotient for the control and PCK2 
knockdown cells was calculated using the metabolite abundance values. The control ratio was 
normalized to one and the PCK2 knockdown ratio was compared to the control using a Student’s 
t-test. (Bottom) A schematic is presented showing the proposed alterations to the TCA cycle. 




However, the maximum respiratory response of the HCECs was marginally decreased with PCK2 
depletion. One explanation for this result could be that PCK2 depletion in the normal cells leads 
to a slightly depolarizing effect of the mitochondria membrane potential. Therefore, the addition 
of FCCP, a mitochondrial uncoupler, would not cause the level of depolarization when compared 
to the control. Another explanation for the decrease in maximum respiratory response would be 
that a compensatory mechanism in the HCECs with PCK2 knockdown was capable of keeping 
the cells working effectively, but not to the same degree as the control cells. Therefore, the 
HCECs may not be functioning at their highest metabolic capacity, especially under stress, with 
the loss of PCK2. It has been shown that PCK2 is sensitive to the integrated stress response (ISR) 
within the cell448. Without PCK2, this stress response may have to rely on a less competent 
mechanism. Although PCK2 may be playing an important role in HCECs, the normal cells cope 
with the loss much more efficiently than the cancer cells. One question is why it appears there is 
more cleaved PARP in control HCECs than there is in control cancer cells. This is likely because 
normal cells have a cell death mechanism that is intact, leading to healthy programmed cell death. 
However, the cleaved PARP is not attenuated by PCK2 depletion. This is in contrast to cancer 
cells that oftentimes bypass natural cell death mechanisms leading to what appears to be less 
cleaved PARP, which is enhanced by PCK2 depletion.  Lastly, the glycolytic capacity of the 
HCECs is slightly decreased under PCK2 depleted conditions. This can be attributed to the fact 
that normal cells are likely undergoing a lower amount of gluconeogenesis. Without PCK2, this 
process cannot be performed, thus leading to a slightly lower glycolytic capacity. 
As we show the importance of PCK2 in colon cancer cells, it is interesting to note which 
inhibitors enhance tumor cell death. One group showed that troglitazone treatment leads to a 
decrease in PEPCK gene expression in hepatocytes501. Troglitazone is a TZD (thiazolidinedione), 
which are known to activate PPARγ, though it appears to inhibit PEPCK independent of this role. 
However, troglitazone contains a vitamin E moiety that is not present on other TZDs, suggesting 




PEPCK inhibitor in colon cancer, but it was determined that the inhibitor used was for the 
cytosolic isoform148. Another inhibitor, 3-mercaptopicolinic acid (3-MPA) has been thought to 
inhibit PCK proteins because a decrease in gluconeogenesis was observed following treatment503-
505. However, it is not definitively known if the compound inhibits one PCK isoform or both. 
More recently, a compound with a 3-alkyl-1,8-dibenzylxanthine nucleus, coined iPEPCK-2, was 
developed using the PCK2 structure506. iPEPCK-2 was shown to inhibit cell growth and survival 
more effectively than that of 3-MPA. Although these studies were performed in vitro and in 
murine animals, it would be more pertinent to treat another in vivo model given the low 












































After extensive analysis of the FUSION screen to identify KSR1-like analogs, 
TIMELESS was evaluated as the one of the most significantly related proteins to KSR1. These 
results show that TIMELESS mRNA is upregulated in human colon tumor cells compared to 
normal tissues. Similar to that of KSR1, TIMELESS protein and mRNA are overexpressed in 
colon cancer cell lines compared to non-transformed human colon epithelial cells. Given the 
prominent role of TIMELESS in regulating the circadian rhythm, it was not surprising to observe 
TIMELESS expression oscillating in a circadian fashion. However, in HCT116 cells, TIMELESS 
expression is constitutively high at all time points. Since TIMELESS negatively regulates the 
circadian rhythm, these data suggest that there is significant dysfunction in the circadian rhythm 
in cancer. Given that TIMELESS is degraded in response to light (127, 128, 130, 147-151), it is 
plausible that shift work could enhance tumorigenesis.  However, future work should include how 
dephosphorylation and other degradation mechanisms effect TIMELESS to retrain the circadian 
rhythm in cancer cells.  
Work presented here also demonstrates that TIMELESS is necessary for colon cancer cell 
viability and proliferation. Although these data are compelling, PARP inhibitor treatment in 
combination with TIMELESS depletion would presumably show synergistic cell death in colon 
cancer cells without negatively effecting normal cells. This would be especially interesting given 
that TIMELESS depletion itself does not appear to increase the percentage of cells in sub-G1, 
suggesting that apoptosis is not enhanced following TIMELESS knockdown, despite a marginal 
increase in cleaved PARP. 
The cell cycle profile of TIMELESS depleted cells suggests that TIMELESS knockdown 
pushes cells into the G2 phase, suggesting a G2/M arrest. Further analysis confirmed this 
mechanism by showing phosphorylation of CHK1 leads to subsequent phosphorylation and 







Figure 7.1: Summary schematic of the potential role of TIMELESS in colon cancer cells 
TIMELESS is enhanced through oncogenic Ras signaling of the MAPK pathway, specifically 
through ERK activation. TIMELESS inhibits γH2AX and phosphorylation of CHK1. 
Subsequently, this leads to downregulation of phosphorylated CDK1, through activation of Wee1 








After the downstream pathway of TIMELESS was elucidated, at least in part, the 
upstream effectors of TIMELESS overexpression were evaluated. Although TIMELESS was 
detected in a FUSION screen to evaluate KSR1-like proteins, we did not expect KSR1 to directly 
regulate TIMELESS. This was confirmed as we knocked down KSR1 and saw no change in 
TIMELESS protein. However, when oncogenic Ras was added to normal cells, TIMELESS 
protein expression increased at various timepoints following synchronization, but then remained 
sustained. This is in contrast to wild type HCECs which we observed the height of TIMELESS 
protein expression around 12-18 hours with a subsequent decrease in protein expression. These 
data show that oncogenic Ras is driving the enhanced expression of TIMELESS in colon cancer 
cells.  
MAPK signaling is driven by oncogenic Ras, so we began to investigate how this 
signaling pathway effects TIMELESS protein expression. Following ERK knockdown, we show 
a marginal decrease in TIMELESS protein expression. However, with the ERK inhibitor, 
SCH772984, a majority of cell lines decreased TIMELESS protein expression substantially. 
Similarly, in HCECs with added oncogenic Ras, the ERK inhibitor was enough to oblate 
TIMELESS protein expression. In HCT15 and FET cells, in which the ERK inhibitor did not 
affect TIMELESS protein expression, it is possible that mutational differences in the cell lines 
could be causing the differential effects. Further work should focus on analysis of the mutational 
profile of the cell lines to understand how the different mutations can affect the response seen 
following the ERK inhibitor.  
Lastly, we further characterized how the ERK is enhancing TIMELESS protein 
expression. Initially, we hypothesized that the ERK inhibitor was decreasing transcription of 
TIMELESS mRNA. Upon analysis of total TIMELESS mRNA, we did not see any change 
following addition of the ERK inhibitor in HCT116 cells. In order to analyze the translational 
capacity of HCT116 cells to enhance TIMELESS mRNA, we isolated polysome-bound mRNA 




that ERK activation preferentially translates TIMELESS mRNA. Taken together, this may lead to 
future work that proteins functionally related to KSR1 are preferentially translated, effecting the 
overall translational landscape of colon cancer cells. 
 
Final Thoughts 
Oncogenic Ras, through increased ERK activation, drives the overexpression of 
TIMELESS in cancer. TIMELESS promotes high fidelity DNA synthesis and reduces the 
accumulation of DNA damage to support rapid cancer cell proliferation through avoidance of cell 
cycle checkpoint G2/M arrest. These results demonstrate a role for TIMELESS in cancer and 
suggest further examination of the link between the circadian cycle and cell cycle, particularly in 
the context of cancer, could reveal novel therapeutics. 
 
PGC1𝛽 – ERR𝛼 signaling axis 
The results presented here describe a unique metabolic and redox mechanism used in 
colon cancer cells to enhance tumorigenic properties. We built off previous literature citing 
PGC1𝛽 and ERR𝛼 as driving forces of metabolism in colon cancer cells, but not non-transformed 
colon cells. This was shown in the context of oxidative phosphorylation and glycolysis, two 
major metabolic pathways in cells. We show that after knockdown of PGC1𝛽, and subsequent 
inhibition of ERR𝛼 signaling, that several metabolic alterations were observed compared to 
control cells, including decreases in baseline oxygen consumption rate, maximal respiratory 
capacity, glycolysis, and glycolytic capacity. These data demonstrate that PGC1𝛽 and ERR𝛼 
signaling are vital for metabolic functions in colon cancer cells.  
 To understand the mechanism used by PGC1𝛽 to enhance cellular growth, the role 
PGC1𝛽 signaling plays in redox pathways was also evaluated. Following knockdown of PGC1𝛽 




depletion of a major antioxidant transcription factor, Nrf2. This observation suggests that in colon 
cancer cells, PGC1𝛽 suppresses mitochondrial ROS to increase the function of mitochondrial 
metabolism. However, this is conflicts with the data suggesting that PGC1𝛽 suppresses oxidative 
phosphorylation, which is thought to produce a large amount of ROS through the different 
complexes involved507-512. One reconciliation of these conflicting data could be found in the fact 
that complex I produces a large amount of ROS but through reverse electron transport513-516. In 
this case, electrons do not proceed in a normal fashion, this causes a large amount of ROS and 
would also cause a decrease in oxidative phosphorylation. Another paradoxical explanation could 
be that when respiratory chain activity is low, the NADH/NAD+ ratio will increase, due to the 
strong reduction of NAD+, and lead to enhanced ROS production514,517. Lastly, another 
explanation could be that PGC1𝛽 knockdown increases only certain complexes of the electron 
transport chain, such as Complex I or Complex III. This could cause an increase in ROS but 
without the support of the other complexes, the oxidative phosphorylation capacity would be 
limited. However, further work investigating these hypotheses would need to be done to fully 
understand the mechanism.  
Originally, our hypothesis was that PGC1𝛽 drove Nrf2 transcriptional activity, given the 
coactivator function of PGC1𝛽. However, when this was analyzed by Western blot, PGC1𝛽 did 
not appear to be regulating the protein expression of Nrf2. Then, the reverse experiment was 
performed in which we tested whether Nrf2 was regulating PGC1𝛽 protein expression. Indeed, 
the Western blot experiment knocking down Nrf2 in colon cancer cells showed a decrease in 
PGC1𝛽 and ERR𝛼 protein expression in HCT116 cells and a marked decrease of PGC1𝛽 protein 
expression in additional cell lines. This suggests that, at least in part, Nrf2 is regulating PGC1𝛽 
signaling. In order to understand the regulatory mechanism, we attempted to determine the levels 
of PGC1𝛽 mRNA following Nrf2 knockdown, yet we could not identify accurate primers or 




short half-life of Nrf2, it was difficult to determine protein stability of PGC1𝛽 via Western blot.  
Despite significant effort, we were unable to determine the specific mechanism used by Nrf2 to 
drive PGC1𝛽 protein expression, whether it be through transcriptional, post-translational, or 
protein stability mechanism. The role of Nrf2 in colon cancer cells have not been thoroughly 
evaluated in the literature so we began to investigate the necessity of Nrf2 in colon cancer cells. 
Through our analysis, we determined that Nrf2 is necessary for the cell viability of colon cancer 
cells to a moderate degree. Since there is very little literature citing the regulatory mechanism of 
Nrf2 in colon cancer, we began to study the driving force behind Nrf2 expression. Considering 
previous reports have shown oncogenic drivers of Nrf2, we examined to potential role of K-Ras, 
a major oncogenic driver of colon cancer, as a regulator of Nrf2. In three colon cancer cell lines, 
knockdown of K-Ras protein also leads to a decrease in Nrf2 protein expression. This observation 
suggests that, similar to lung cancer176, K-Ras drives Nrf2 protein expression in colon cancer 
cells. These data may also suggest that Nrf2 is intermediatory between K-Ras and PGC1𝛽 as 
previous reports have shown K-Ras to drive PGC1𝛽 expression as well. However, there are other 
mechanisms that regulate PGC1𝛽 including KSR1, Myc, and HIF-1110,112,113,205. Although not all 
these data have been shown to be necessary for colon cancer cell survival or tumor progression. 
Similarly, there could be many intermediates between the regulation of PGC1𝛽 by K-Ras.  
 Previous reports have shown that there is little to no expression of PGC1𝛽 or ERR𝛼 in 
normal, non-transformed, human colon epithelial cells. We also observed this, as well as seeing 
relatively little expression of Nrf2. However, once we exogenously overexpressed Nrf2 through 
transfection of a FLAG-Nrf2 construct, we were surprised to see that this alone was enough to 
observe robust expression of both PGC1𝛽 and ERR𝛼 protein. These data suggest that Nrf2 may 
be enhancing metabolism in normal colon cells, similar to that of cancer cells, through PGC1𝛽 
signaling. Studies should be done to determine whether this enhanced metabolism would be 




 Many chemotherapeutics use ROS-inducing mechanisms to initiate cell death. Because 
of these reports, we began to evaluate the role of Nrf2 in colon cancer cells following treatment 
with a common chemotherapeutic, Oxaliplatin. A relatively high dose of Oxaliplatin was added to 
the cancer cells and lysates were prepared at subsequent time points. Our data suggest that within 
a few hours of adding the chemotherapeutic, we see an increase in Nrf2 expression, and assumed 
subsequent antioxidant signaling. This suggests that the chemotherapeutic is in fact inducing ROS 
in the cancer cells, and that Nrf2 may be employed to mitigate cancer cell death. However, by 24 
hours following treatment, Nrf2 protein expression is back to that of the controls, potentially even 
lower than the controls. This observation may suggest that Nrf2 performed the job of reducing 
ROS levels and, at least some of the cells, are beginning to recover. One way to combat this 
would be to inhibit Nrf2 activity in addition to treating cells with a chemotherapeutic. This could 
inhibit the cells from combating the high levels of ROS leading to synergistic tumor cell death.  
  The PGC1𝛽 and Nrf2 signaling data begin to diverge when we look at the health of the 
mitochondria through a readout of mitochondrial membrane potential. Our initial hypothesis was 
that the large increase in mitochondrial ROS following PGC1𝛽 or Nrf2 knockdown would lead to 
a dysfunction in the mitochondria through an unbalanced potential across the mitochondrial 
membrane. Though we observed a decrease in mitochondria membrane potential when Nrf2 was 
knocked down, we did not detect a significant change in mitochondrial membrane potential 
following PGC1𝛽 knockdown compared to the control cells. When we deconvolved the data, we 
were observed a coincident increase in mitochondrial content, and mitochondria membrane 
potential. These data suggest that there is a large increase in either size or number of healthy 
mitochondria following PGC1𝛽 knockdown. One explanation for this data would be that there is 
a defect in specific complexes of the electron transport chain causing more mitochondria with 
appropriate membrane potential but is dysfunctional in terms of oxidative phosphorylation.  
Specifically, a study showed that PGC-1 overexpression increased ATP synthase mRNA levels in 




increase in fatty acid oxidation and components of the electron transport system519.  
Another explanation for this observation may be the paradoxical concept that 
mitochondrial biogenesis is increased by mitochondrial damage from oxidative stress. We suggest 
that PGC1𝛽 knockdown increases oxidative stress and subsequently enhances mitochondrial 
biogenesis520,521. Some genes required for mitochondrial biogenesis are regulated through the 
transcription of mitochondrial DNA, which is increased by TFAM and TFB2M. TFAM and 
TFB2M proteins can be increased following an increase in mitochondrial oxidative stress, which 
leads to enhanced mitochondrial biogenesis522. Following an increase in ROS, Nrf2 activates 
heme-oxygenase 1 (HO-1), which sustains TFAM expression during mitochondrial biogenesis523-
525. It appears that ROS may be subdued by PGC1𝛽 through a different mechanism than ROS 
inhibition by Nrf2.  
Another indication that Nrf2  functions separate its regulation of PGC1𝛽 is revealed by 
oxygen consumption rate of cells following RNAi of each effector. Though there are reports that 
Nrf2 can drive metabolic pathways such as mTORC1 and PPP526,527, we do not see evidence of 
that in our Seahorse experiment. One explanation for the lack of regulation of metabolism by 
Nrf2 could be that itaconate, a metabolite that inhibits succinate dehydrogenase, can alkylate 
Keap1 cysteines allowing for the translocation of Nrf2 to the nucleus528. Similarly, many target 
genes of Nrf2 have also been shown to participate in the regulation of glycolysis, pentose 
phosphate pathway, and glutamine metabolism141,529-531, though some of the targets have been 
shown to have non-metabolic functions532. Given the conclusion from the literature, it is curious 
why we do not see a decrease in oxygen consumption rate with Nrf2 knockdown in CRC cell 
lines. One explanation for this result could be the evidence that increased protein production 
under oxidative stress can lead to protein misfolding or proteotoxic stress533,534. In order to avoid 
this stress, Nrf2 controls the expression of many proteasome subunits, promoting the degradation 
of misfolded proteins534,535. Similarly, Nrf2 can stimulate autophagy-related genes and induce 




would be necessary to confirm these results, it is possible that Nrf2 is modulating these processes 
following excessive oxidative stress resulting in a lack of regulation of oxidative phosphorylation, 
despite its regulation of PGC1𝛽. 
 Due to the divergence of the PGC1𝛽 and Nrf2 data, we began to look downstream of 
PGC1𝛽 and ERR𝛼 to understand the mechanism by which these two proteins enhanced metabolic 
processes in colon cancer cells to sustain tumorigenic properties. We began by performing RNA 
sequencing on cells with knockdown of either PGC1𝛽 or ERR𝛼 as well as a non-targeting 
control. Following analysis of this data, we identified several pathways downregulated that are in 
common with both PGC1𝛽 and ERR𝛼 knockdown. One major enzyme that was identified as 
downregulated at nearly the highest significance of both PGC1𝛽 and ERR𝛼 knockdown was 
PCK2. We validated that PGC1𝛽 and ERR𝛼 knockdown decreases PCK2 protein expression and 
mRNA expression in two colon cancer cell lines. Given the relatively little data available on 
PCK2 in colon cancer, we began exploring the role of PCK2 in colon cancer cell viability and 
metabolism. First, we showed that PCK2 is necessary for cell viability in colon cancer cells, but 
not normal cells.  
Then, we repeated the experiments done in PGC1𝛽 depleted cells investigating oxidative 
phosphorylation and glycolysis. Indeed, we see a repeat in the data, following PCK2 depletion 
there were corresponding decreases in baseline oxygen consumption rate, maximum respiratory 
rate, glycolysis and glycolytic capacity. In contrast, we did not see these same depletions when 
PCK2 was knocked down in normal colon cells.  These data suggest that PCK2 is either not as 
vital to normal cells as it is to cancer cells or that normal cells are better able to compensate 
following PCK2 depletion than cancer cells. This is further supported by the fact that there is no 
detectable PGC1𝛽 or ERR𝛼 protein expression in HCECs, suggesting a different mechanism by 






Figure 7.2: Summary schematic of the PGC1𝛽 – ERR𝛼 signaling axis in colon cancer cells. 
(A) These data demonstrate K-Ras as a regulator of Nrf2. Then, Nrf2 regulates PGC1𝛽 signaling 
to, in part, suppress ROS and enhance survival. (B) Independent of (A), PGC1𝛽 and ERR𝛼 
regulate PCK2 activity which enhances metabolic processes such as oxidative phosphorylation 








Furthermore, we sought to identify how different carbon sources, glucose or glutamine, 
effect PCK2 depleted cells. We added increasing concentrations of glucose or glutamine to both 
control and PCK2 depleted colon cancer cells. Increasing doses of glucose caused baseline 
oxygen consumption rate to exceed that of the control in the PCK2 knock down cells. However, 
increasing glutamine did not affect baseline OCR in the PCK2 knockdown cells. This suggests 
that glutamine is being utilized by PCK2 to enhance cellular metabolism. Although glucose and 
glutamine are two of the main substrates used by cancer cells to fuel the TCA cycle, there are 
other substrates that could be used based on nutrient availability. Lactate, a byproduct of glucose, 
has been shown to be preferentially used over glucose to enhance the TCA cycle124,495,539,540. It 
was recently shown thatCRC cells use lactate as a substrate for the TCA cycle and a decrease in 
PCK1 decreases lactate utilization541, suggesting that further analysis may need to be done to 
understand the specific mechanism of PCK2 in CRC cells.  
Due to the major role PCK2 plays in the proper function of the TCA cycle485, we 
investigated the metabolites integral to the TCA cycle. We observed a large increase in 
oxaloacetate and a decrease in phosphoenolpyruvate. This observation confirms that PCK2 in 
CRC cells is fulfilling its canonical function of converting oxaloacetate to phosphoenolpyruvate. 
We also observed an increase in fumarate and succinate as well as a decrease in the citrate and 
isocitrate pool. After calculating the reaction quotient compared to the equilibrium constant of the 
malate dehydrogenase enzyme, we determined that the ratio is much lower in the PCK2 depleted 
cells compared to the control cells. This suggests that this vital reaction in the TCA cycle is 
dysfunctional in PCK2 depleted cells, potentially even backing up or reversing the flow of the 
cycle. This is confirmed that the fumarate and succinate metabolites are high, because they cannot 
be adequately pushed through the cycle. This also explains why the citrate and isocitrate pool is 
decreased following PCK2 knockdown. In contrast, we did not see a difference in malate between 
the control cells and the PCK2 knockdown cells. One explanation for this is this is that the malic 




the mitochondria and turned into phosphoenolpyruvate by PCK1 in the cytoplasm, which would 
cause a more balanced level of malate.  
 The effect of hypoxia on gluconeogenesis enzymes is not well studied. However, one 
study does suggest that hypoxia is a potential activator of gluconeogenesis542. In contrast, 
intermittent hypoxia inhibits PCK2 and reduces glucose levels in HCC543. This may suggest that 
the influence of hypoxia on gluconeogenesis is associated with PCK2 expression. Interestingly, in 
HepG2 cells, PCK1 protein levels were reduced following increasing time under hypoxic 
conditions, while PCK2 levels were constitutive and stable regardless of time in hypoxia462. 
These observations may suggest that PCK2 is compensating for PCK1 during hypoxic stress. 
This may also be dependent upon hormonal regulation of PCK1, while PCK2 is constitutively 
expressed448,458. Similarly, hypoxia is capable of reprogramming the TCA cycle through 
accumulation of fumarate and an increase in ROS levels in breast cancer cells544. These 
observations may tie together the redox and metabolic phenotypes regulated by PGC1𝛽. 
 This work is limited by the lack of in vivo studies to substantiate that PCK2 plays a vital 
role in tumorigenic properties. Cells in vitro may not give an accurate representation of the true 
mechanism taking place. However, in vivo models pose a problem given the unbalanced ratio of 
PCK1 to PCK2 protein levels in murine organisms. To circumvent this issue, 3D culture of 
patient derived organoids may be helpful as they have been shown to better recapitulate the 
disease545. Similarly, although two validated siRNA oligos were used in these experiments, there 
is a possibility that residual PCK2 expression is enough to drive signaling and therefore skew the 
results shown. Gene-editing to ensure complete protein knockout would be beneficial to avoid 
any further signaling and increase confidence in the results. It is also possible that there is 
compensation by PCK1 following PCK2 depletion, given that there are several studies showing 
PCK1 is vital in cancer cells. Future work should include the understanding of PCK1 expression 
and function, especially following PGC1𝛽 or PCK2 knockdown.  




PGC1𝛽, further work should include evaluation of mitochondrial ROS following PCK2 
knockdown to determine if the data seen when PGC1𝛽 is knocked down is consistent. Given the 
knockdown of PCK2 has a major effect on the TCA cycle and other metabolic pathways, I would 
expect dysfunction in the electron transport chain and thus an increase in ROS. Similarly, it 
would be interesting if the knockdown of PCK2 activated the antioxidant system following an 
increase in ROS, providing a potential link between Nrf2 and PCK2.  
Further work should also be focused on other targets of PGC1𝛽 including ASCT1 or 
ASNS, which are significantly downregulated by knockdown of either PGC1𝛽 or ERR𝛼. The 
increase in ASCT1, a potential transporter of glutamine, which is induced by PGC1𝛽 signaling, 
may explain the enhancement of oxidative phosphorylation and large decrease of ROS. Similarly, 
ASNS which is responsible for converting Aspartate into Asparagine through the reduction of 
Glutamine to Glutamate, may cause dysfunction in the TCA cycle, expanding upon the effects 
seen with PCK2 depletion. It may also be relevant to examine other downregulated pathways 
seen with PGC1𝛽 or ERR𝛼 knockdown including serine metabolism and the Pentose Phosphate 




These results reveal a novel mechanism of metabolic reprogramming in colon cancer. 
This signaling pathway links the redox vulnerability in cancer to the metabolic needs of the 
rapidly growing cells. It is clear that PGC1𝛽 signaling regulates both oxidative stress and 
metabolic homeostasis. Nrf2 and PCK2 are at the crossroads of these processes and are key 
players required for cancer cells to survive and maintain their growth and viability.  
Overall, these results demonstrate the necessity of PGC1𝛽 signaling as a potential 




These data also create opportunities for further understanding metabolic reprogramming by 
examining the other significant genes and pathways regulated by PGC1𝛽 and ERR𝛼 signaling. 
Further characterization of the pathway identified here as well as additional factors in play 
through in vivo and patient derived samples will hopefully lead to the development of targeted 




















       
      Appendix A: HCT116 cells incubated in hypoxic conditions 
Rationale:  
One downfall of comparing HCT116 cells to HCECs is that we culture HCECs in a 2% 
oxygen hypoxia chamber while the cancer cells are cultured in ambient oxygen. One attempt to 
ensure that this does not skew the results presented here is by incubating HCT116 cells in the 
hypoxia chamber.  
Results/Discussion: 
Following incubation in the hypoxia chamber for several days, we collected HCT116 
cells and compared them to the cells grown at ambient oxygen. From our Western blot analysis, 
the cells grown in hypoxic conditions did not have a change in the antioxidant response genes 
Nrf2 or NQO1 (Figure A.1). This suggests that despite the hypoxic conditions, the cancer cells 
can be accurately compared to the HCECs. This study lacks completeness since it did not 
evaluate other metabolic processes, ROS, or mitochondrial membrane potential under hypoxic 
conditions. Similarly, the cancer cells would likely have to be grown in hypoxic conditions for a 




















Figure A.1 Nrf2 and NQO1 are not affected following incubation of HCT116 cells in low 
oxygen. Lysates of HCT116 cells incubated in 2% oxygen (Low Ox) or ambient oxygen (Norm 
Ox) for 72-hours were immunoblotted for Nrf2 and NQO1 protein expression with 𝛽-actin and 
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